Effective ness o f On a botulinu m to x in A  ( Bot ox ® )  i n P ed ia tr i c
Patients Exper i encing M igraines: A  Ran do m i zed D o uble
Blinded P laceb o  C rossover Stu d y in t h e Pe dia tr i c Pai n
Populatio n
[CONTACT_649969] S h ah, M. D . , M B A
Director,  Pain  Serv i ces  U C I  H e a lth
[STUDY_ID_REMOVED] | J anua ry [ADDRESS_871666] i ons
Protoco l Narrat i ve  ~  Exped i ted / Fu ll Comm i ttee
Biomed i ca l/ C li n i ca l Research
Version  2015
Upload  t his  comple t ed  narra t ive  and  any  supplemen t al  documen t a t ion
to the  I RB  Applica t ion .IRB USE  ONLY  –
HS#:  2016-3108
Lead  Researcher  Name:  [CONTACT_649966] , MD
Study  T i t l e:  E ff ec t iveness  o f Onabo t ulinum t oxin  A  (Bo t ox®)  in  Pedia t ric  Pa t ien t s  Experiencing
Migraines : A  Randomized  Double  Blinded  Placebo  Crossover  S t udy  in  t he  Pedia t ric  pain  popula t ion
CLIN I CAL  TR I AL  MASTER  PROTOCOL  AND  I NVEST I GAT I ONAL  BROCHURE  I NFORMAT I ON  *
Master  Protoco l
Version  # :
Version  Da t e :Invest i gator
Brochure:
<Speci f y
Drug / Device>Invest i gator
Brochure:
<Speci f y
Drug / Device>Sponsor
Consent
Form
Temp l ate(s)
[ ] This  s t udy  is  inves t iga t or-au t hored  (inves t iga t or  developed  t he  s t udy  and  is  conduc t ing  t he  s t udy
at UC I and / or  wi t h  o t her  non-UC I si t es) .
* Add  columns  as  applicable
NON-TECHN I CAL  SUMMARY
Provide  a  brie f non- t echnical  summary  or  synopsis  o f t he  s t udy  t ha t can  be  unders t ood  by  I RB  members
with varied  research  backgrounds , including  non-scien t is t s  and  non-a ff ilia t ed  members .
Headaches  are  t radi t ionally  charac t erized  as  acu t e , f requen t, severe  or  t hrobbing / dull  pain  localized  t o
the face  or  neck . Analgesics  can  be  prescribed  or  acquired  over- t he-coun t er , depending  on  t he  severi t y
of the  ailmen t, as  a  common  remedy  t o  relieve  pain  and  associa t ed  symp t oms . Curren t ly , preven t a t ive
measures  have  emerged  as  a  means  t o  improve  t he  quali t y  o f li f e  o f pa t ien t s  a ff ec t ed  by  [CONTACT_649959] . Bo t ulinum  Toxin  Type  A  (Bo t ox®) , or  onabo t ulinum t oxinA , is  an  FDA-approved
neuro t oxin  developed  by  [CONTACT_78562]  I nc . f or  t rea t ing  chronic  headaches  and  migraines  in  adul t s , however
there  is  limi t ed  scien t i f ic  li t era t ure  on  t he  ou t comes  o f pedia t ric  pa t ien t s  aged  8-17  receiving
onabo t ulinum t oxinA . The  purpose  o f t his  s t udy  is  t o  de t ermine  t he  e ff ec t iveness  o f Bo t ox®  injec t ions  in
pedia t ric  pa t ien t s  f or  t he  t rea t men t o f chronic  headache  and  common  migraine  in  t he  pedia t ric
popula t ion . We  wan t t o  examine  t he  long- t erm  ou t comes  o f pa t ien t s  who  received  onabo t ulinum t oxinA
inject ions  a t UC  I rvine  Heal t h  f or  migraines  and  de t ermine  i t s  e ff ec t iveness  f or  pedia t ric  pain  use .
UCI IRB A pp rov ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  [ADDRESS_871667] I ON  1:  PURPOSE  AND  BACKGROUND  OF  THE  RESEARCH
1. Provide  t he  scien t i f ic  or  scholarly  ra t ionale  f or  t he  research . Describe  t he  relevan t background
informa t ion  and  t he  speci f ic  gaps  in  curren t knowledge  t ha t t his  s t udy  in t ends  t o  address .
Background
Chronic  headache  and  migraine  are  one  o f t he  mos t common  pain  complain t s  in  children  and
adolescen t s , bo t h  t o  t he  primary  care  provider , as  well  as  t o  t he  pain  physician  specializing  in  pedia t ric
pain disorders . Prevalence  o f migraine  in  younger  children  is  approxima t ely  10% , and  up  t o  28%  o f
adolescen t s  su ff er  f rom  recurren t headaches , t he  majori t y  o f which  have  migrainous  f ea t ures . [ 3 , 4 ]
Aydin  e t al  repor t ed  t he  mos t common  headache  presen t a t ion  in  pedia t ric  neurology  prac t ices  was
migraine  t ype , comprising  57 . 1%  o f all  headaches  presen t ing  f or  ini t ial  consul t a t ion .[ 5 ] Popula t ion
studies  have  demons t ra t ed  t ha t over  130 , 000  school  days  are  missed  every  t wo  weeks  and  3  million
bedridden  days  occur  per  mon t h  as  a  resul t o f pedia t ric  migraine .[ 6 ] Common  migraine  is  a  debili t a t ing
disorder  t ha t requires  bo t h  a  plan  t o  reduce  t he  severi t y  o f a tt acks , as  well  as  a  prophylac t ic  plan  t ha t
reduces  t he  f requency  o f occurrence . Epi[INVESTIGATOR_649952] t ed  wi t h  migraine  include  recurren t
gastroin t es t inal  dis t urbance , cyclic  vomi t ing  syndrome  and  abdominal  migraine , benign  paroxysmal
vertigo , and  benign  paroxysmal  t or t icollis .[ 7 ] Powers  e t al  demons t ra t ed  t he  nega t ive  impac t o f having
childhood  migraine  on  overall  quali t y  o f li f e  is  similar  t o  pedia t ric  cancer , hear t disease  and  rheuma t ic
disease  [ 8 ] As  t he  f requency  o f migraine  a tt acks  increase , so  does  propor t ionally  t he  child’s  disabili t y  in
lost school  t ime  and  f amily  and  social  in t erac t ions , all  o f which  may  lead  in  t urn  t o  economic  disabili t y .
Compared  wi t h  epi[INVESTIGATOR_649953] , pa t ien t s  wi t h  chronic  migraine  have  a  lower  socioeconomic
status , reduced  heal t h-rela t ed  quali t y  o f li f e , grea t er  psychia t ric  and  medical  comorbidi t ies , and
increased  occupa t ional  disabili t y . [ 9 ] S t ang  e t al  es t ima t ed  t he  heal t h  care  cos t s  are  70%  higher  f or  a
family  wi t h  a  migraine  t han  a  non-migraine  a ff ec t ed  f amily , and  direc t medical  cos t s  f or  children  wi t h
migraine  are  repor t ed  t o  be  similar  t o  t hose  f or  adul t s . [ 6 ]. A  s t udy  published  in  JAMA  2003  f ound  t ha t
healt h  care  cos t s , work-rela t ed  disabili t y  f or  paren t s  and  los t educa t ional  oppor t uni t y  f or  t he  child  leads
to an  annual  economic  impac t in  t he  US  o f approxima t ely  $36  billion  due  t o  bo t h  direc t medical  cos t s
and los t produc t ivi t y  in t o  adul t hood .[ 10 ]
Onabo t ulinum t oxinA
Botulinum  neuro t oxin-A  is  a  puri f ied  neuro t oxin  complex  produced  by  t he  anaerobic  bac t erium
Clost ridium  bo t ulinum . [ 11 , 12 ]. The  main  mechanism  o f ac t ion  o f bo t ulinum  t oxin  involved  t he  t arge t ing
of the  neuromuscular  junc t ions  by  [CONTACT_3163]  o f a  speci f ic  cleavage  o f t he  soluble  N-e t hylmaleimide-
sensi t ive  f ac t or  (NSF)-a tt achmen t pro t ein  recep t or  complex  (SNARE)-like  synap t osomal-associa t ed
protein  o f 25kDa  (SNAP-25)  [ 11 , 12 ]. The  f inal  ou t come  o f t his  mul t i-s t ep  process  is  t he  inhibi t ion  o f
pain neuro t ransmission  (i . e . Chemo  denerva t ion) , including  t he  inhibi t ion  o f t he  release  o f migraine-
related  neuropep t ides  (eg  CGRP  and  SP)  and  glu t ama t e . [ 11 , 12 , 13 ]
Onabo t ulinum t oxinA  was  approved  by  t he  FDA  in  2010  f or  adul t pa t ien t s  wi t h  common  migraine , wi t h
the indica t ion  o f >15  headache  days  per  mon t h , wi t h  headache  las t ing  4  or  more  hours  each  day  in
people  18  years  or  older . BOTOX ® preven t s  up  t o  9  headache  days  a  mon t h  (versus  up  t o  7  in
placebo)  and  is  injec t ed  every  3  mon t hs . [ 14 , 15 ]
While  randomized , double  blind , placebo-con t rolled  t rials  evalua t ing  Onabo t ulinum t oxinA  e ff icacy  in
migraine  prophylaxis  in  adul t li t era t ure  demons t ra t es  s t a t is t ically  signi f ican t resul t s  t owards  sa f e t y  and
efficacy  [ 14 , 15 ], no  such  randomized , double  blind  placebo  con t rolled  da t a  f or  sa f e t y  or  e ff icacy  exis t s
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 of 29
in the  pedia t ric  popula t ion . I n  a  re t rospec t ive  case  series  by  [INVESTIGATOR_47269]  e t al  t o  assess  t olerabili t y  and
efficacy  o f Onabo t ulinum t oxinA  in  10  f emale  pa t ien t s  aged  11-17years , f our  pa t ien t repor t ed  subjec t ive
but clinically  relevan t relie f in  headache  in t ensi t y , and  2  pa t ien t s  no t ing  bo t h  decrease  in  in t ensi t y  and
frequency . The  f our  responders  also  repor t ed  improvemen t s  in  quali t y  o f li f e . [ 16 ] Chan  e t al
prospec t ively  evalua t ed  12  adolescen t f emales  wi t h  migraine  and  chronic  daily  headache , 6  o f which
were  long  t erm  pa t ien t s . They  repor t ed  all  long  t erm  pa t ien t s  had  improvemen t in  headache  symp t oms ,
which  decreased  on  average  33-75% , and  improvemen t in  quali t y  o f li f e . [ 17 ] Kabbouche  e t al  also  in
another  re t rospec t ive  s t udy  f ound  s t a t is t ically  signi f ican t improvemen t in  mon t hly  headache  f requency
in 45  pedia t ric  chronic  daily  headache  pa t ien t s  who  par t icipa t ed  in  252  Onabo t ulinum t oxinA  injec t ions
(average  dose  188 . 5  + / -  32  uni t s)  and  an  improvemen t in  pedia t ric  migraine  disabili t y . A  30  poin t
improvemen t in  pedia t ric  disabili t y  scoring  be t ween  f irs t injec t ion  and  f ollow-up  injec t ion  was  also
observed  wi t h  decreased  calcula t ed  disabili t y  f rom  severe  t o  modera t e  on  PedM I DAS . [ 18 ] I n  a  10-year
follow  up  o f case  series  o f Onabo t ulinum t oxinA  in t erven t ion  in  adolescen t s  wi t h  chronic  daily  headache
and cervicalgia , Schroeder  e t al  demons t ra t ed  bo t h  shor t t erm  e ff icacy  on  headache  f requency  and
severi t y , and  in  t he  long  t erm  f ollow  up  (10  years  pos t injec t ion  t herapy) , chronic  daily  headache  was
not exis t en t in  any  o f t he  pa t ien t s . [ 19 ] Common  adverse  even t s  o f Onabo t ulinum t oxinA  repor t ed  in
litera t ure  in  t he  pedia t ric  popula t ion  are  redness  or  t emporary  swelling  a t injec t ion  si t e , t emporary  pain
at injec t ion  si t e , p t osis , and  blurred  vision  [ 17 ]. I n  all  o f t hese  s t udies , comple t ion  o f a  prospec t ive ,
randomized  double  blinded  placebo  con t rolled  t rial  is  highly  recommended  t o  demons t ra t e  objec t ive
outcome  parame t ers  in  e ff icacy  and  t olerabili t y . I n  t he  P I ’s  nearly  5  year  experience  o f using
Onabo t ulinum t oxinA  in  pedia t ric  prac t ice  she  has  seen  drama t ic  improvemen t in  pa t ien t pain  (bo t h  in
intensi t y  and  f requency  o f migraine) , dura t ion  o f ac t ion  o f migraine , school  a tt endance , social
interac t ion , disabili t y  and  reaching  s t uden t ’s  in t ellec t ual  po t en t ial  by  [CONTACT_649960] t ically  t rea t ing  headache
with Bo t ox .
Applica t ions  o f Bo t ulinum  t oxin  A  appears  t o  be  generally  sa f e  in  t he  pedia t ric  popula t ion  f or  o t her
indica t ions , such  as  localized  or  segmen t al  spas t ici t y  disorders , bladder  hyper t onici t y , ves t ibular
migraine  as  young  as  2  years  o f age , al t hough  t he  majori t y  o f t he  class  I and  II s t udies  included
abobo t ulinum t oxinA  (Trade  name  [CONTACT_649967] t ) . [ 21 ] Wi t h  t he  encouraging  da t a  in  adul t s  wi t h  chronic
migraine  presen t ed  a t t he  14 th Congress  o f t he  I n t erna t ional  Headache  Socie t y  (Philadelphia , PA
2009)  and  wi t h  t he  experiences  o f t he  above  ci t ed  re t rospec t ive  case  series , i t cer t ainly  appears
reasonable  t o  f ur t her  explore  a  po t en t ial  role  f or  Onabo t ulinum t oxinA  in  t he  managemen t o f chronic
migraine  in  t he  pedia t ric  popula t ion .
2. Provide  relevan t preliminary  da t a  (animal  and / or  human) .
Sign i f i cance
While  mos t chronic  pain  condi t ions  are  manageable , migraine  pain  can  be  devas t a t ing . Recen t ly ,
Onabo t ulinum t oxinA  was  approved  f or  t he  prophylaxis  o f migraine  symp t oms  by  t he  US  Food  and  Drug
Adminis t ra t ion  (FDA) , which  has  drama t ically  al t ered  t he  way  pain  physicians  approach  migraine  pain .
Unfor t una t ely , mos t adul t s  who  su ff er  wi t h  migraines  have  t heir  f irs t headache  during  childhood  or
adolescence  [ 1 ]. Al t hough  i t appears  t ha t many  preven t a t ive  agen t s  are  sa f e  in  children , none  are
curren t ly  FDA-approved  f or  t his  age  group . As  a  resul t, despi t e  experiencing  signi f ican t disabili t y , t he
vast majori t y  o f children  who  presen t t o  t heir  physician  wi t h  migraine  headache  do  no t receive
prophylac t ic  t herapy . [ 2 ]
Treat men t f or  pedia t ric  head  pain  is  an  ex t rapola t ion  f rom  all  t ha t we  have  learned  abou t adul t
headache  wi t h  t he  exper t ise  o f working  wi t h  children  in  pain . Pedia t ric  pain  medicine  his t orically  has  i t s
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 3 of 29
own challenges , largely  su ff ering  f rom  under-assessmen t or  t rea t men t paradigms  ex t rapola t ed  f rom
adult li t era t ure . Curren t clinical  s t udies , while  able  t o  demons t ra t e  e ff icacy , may  no t demons t ra t e
safet y , or  vice  versa .
The signi f icance  o f t his  s t udy  is  t o  evalua t e  t he  e ff icacy  o f Onabo t ulinum t oxinA  (BOTOX®)  f or  t he
treatmen t and  prophylaxis  o f pedia t ric  migraine  in  a  randomized , double-blinded , placebo  cross  over
study . No  t rials  curren t ly  exis t in  li t era t ure  s t udying  Onabo t ulinum t oxinA  f or  e ff icacy  and / or  sa f e t y  f or
indica t ion  o f pedia t ric  migraine , al t hough  signi f ican t con t ribu t ions  have  been  made  by  [INVESTIGATOR_1312] t rospec t ive
case  series  over  t he  las t 10  years . The  his t orical  and  longi t udinal  con t ex t o f t he  in t eres t t o  design  t his
study  comes  f rom  t he  Principal  I nves t iga t or’s  (P I )  ex t ensive  use  o f “o ff label”  Onabo t ulinum t oxinA  t o
treat re f rac t ory  pedia t ric  migraine  over  t he  las t 5  years . Anecdo t ally , t he  resul t s  are  so  impressive  and
impac tf ul  in  her  pa t ien t s’  lives , t ha t t his  t herapeu t ic  ough t t o  be  s t udied  in  a  con t rolled  se tt ing  t o
demons t ra t e  clinical  ou t come  t o  valida t e  exis t ing  t rea t men t s t ra t egies . Thus , t his  s t udy  seeks  t o  f ul f ill
ASRA’s  goal  o f iden t i f ica t ion  o f novel  applica t ions  o f exis t ing  t herapeu t ics . Moreover , t his  t rial  may
bene f i t an  under-s t udied  pain  popula t ion  wi t h  t he  long- t erm  goal  o f new  FDA  indica t ion  t o  “on  label”
status . The  proposal  also  caries  policy  and  legisla t ive  impac t as  i t f ul f ills  t he  f ederal  ini t ia t ive  t o  design
and conduc t t rials  in  t he  pedia t ric  pain  popula t ion  wi t hin  con f ines  o f t he  Bes t Pharmaceu t icals  f or
Children  Ac t (BPCA)  o f [ADDRESS_871668] udied .
Spec i f i c  A i ms
The proposed  research  is  in t ended  t o  explore  whe t her  pedia t ric  chronic  migraine  may  bene f i t f rom
Onabo t ulinum t oxinA  t rea t men t. The  s t udy  is  f ocused  on  a  speci f ic  debili t a t ing  disorder  o f chronic  pain
in a well-de f ined  popula t ion  t ha t is  his t orically  no t well  s t udied . The  objec t ives  are  a tt ainable  wi t hin  t he
proposed  t ime f rame .
Hypo t hesis :
Aim 1 : To  t es t i f Onabo t ulinum t oxinA  is  superior  t o  placebo  in  reducing  headache  f requency , in t ensi t y
and pedia t ric  migraine-rela t ed  disabili t y  (E ff icacy)
Aim 2 : To  evalua t e  t he  incidence  o f adverse  even t s  o f Onabo t ulinum t oxinA  adminis t ra t ion  in  children
aged  8-17  (Sa f e t y , Tolerabili t y)
Aim 3 : To  evalua t e  i f Onabo t ulinum t oxinA  can  con t ribu t e  t o  reduc t ion  in  preven t ive  and  rescue
medica t ion , reduc t ion  in  heal t h  care  u t iliza t ion  via  emergency  room  and  hospi t al  admissions  and
healt h  care  cos t s  (Hospi t al  and  pharmacy  resource  u t iliza t ion)
Study  aims  f i t t oge t her  in  an  overall  f ramework  such  t ha t primary  and  secondary  ou t comes  are  easily
defined , measureable , and  valida t ed  as  an  accep t able  means  t o  measure  clinical  success  and  t o
longi t udinally  assess  response .
4. Describe  t he  primary  ou t come  variable(s) , secondary  ou t come  variables , and  predic t ors  and / or
comparison  groups  as  appropria t e  f or  t he  s t a t ed  s t udy  objec t ives / speci f ic  aims .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 4 of 29
Primary  outcome:  Absolu t e  number  o f headache  days  per  mon t h .
Secondary  outcomes
Severi t y  o f headache  epi[INVESTIGATOR_1865]
Disabili t y  scoring  (PedM I DAS)
Dura t ion  o f bene f i t assessed  a t every  6  week  in t erval
Change  f rom  baseline  in  t he  f requency  o f severe  headache  days
 Change  f rom  baseline  in  t he  t o t al  cumula t ive  hours  o f headache  on  headache  days  Change  f rom
baseline  in  t he  t o t al  dose  or  in t erval  o f preven t ive  migraine  or  rescue  migraine  medica t ion
Percen t age  o f pa t ien t s  wi t h  ≥ 50%  decrease  f rom  baseline  in  t he  f requency  o f headache  days
Percen t age  o f pa t ien t s  who  are  prescribed  oral  rescue  migraine  prophylac t ic  t rea t men t
 Percen t age  o f pa t ien t s  who  reduce  consump t ion  o f preven t ive  migraine  or  rescue  migraine
treatmen t
 Change  f rom  baseline  in  t he  absolu t e  ED  visi t s  and / or  hospi t al  admission  during  each  t rea t men t
phase
 Percen t age  o f pa t ien t s  experiencing  associa t ed  adverse  even t s , serious  or  non-serious . (Non-
serious  de f ined  as  injec t ion  si t e  swelling , redness , t emporary  pain , p t osis , blurred  vision ,
worsening  o f migraine , nausea , vomi t ing , head  lag  weakness , drooling . )
5. Lis t up  t o  t en  relevan t re f erences / ar t icles  t o  suppor t t he  ra t ionale  f or  t he  research . Do  no t append  an
extensive  N I H-gran t -s t yle  bibliography .
 1. Aurora , S . K ., e t al ., Onabo t ulinum t oxinA  f or  t rea t men t o f chronic  migraine : pooled  analyses  o f t he
56-week  PREEMPT  clinical  program . Headache , 2011 . 51(9) : p . 1358-73 .
2.  Dodick , D . W ., e t al ., Onabo t ulinum t oxinA  f or  t rea t men t o f chronic  migraine : pooled  resul t s  f rom
the double-blind , randomized , placebo-con t rolled  phases  o f t he  PREEMPT  clinical  program .
Headache , 2010 . 50(6) : p . 921-36 .
3. Ahmed , K ., e t al ., Experience  wi t h  bo t ulinum  t oxin  t ype  A  in  medically  in t rac t able  pedia t ric  chronic
daily headache . Pedia t r  Neurol , 2010 . 43(5) : p . 316-9 .
4.  Bon f er t, M ., e t al ., Primary  headache  in  children  and  adolescen t s : upda t e  on  pharmaco t herapy  o f
migraine  and  t ension- t ype  headache . Neuropedia t rics , 2013 . 44(1) : p . 3-19 .
5. Brodsky , J . R ., B . A . Cusick , and  G . Zhou , Evalua t ion  and  managemen t o f ves t ibular  migraine  in
children : Experience  f rom  a  pedia t ric  ves t ibular  clinic . Eur  J  Paedia t r  Neurol , 2016 . 20(1) : p . 85-
92.
6. Chan , V . W ., E . J . McCabe , and  D . L . MacGregor , Bo t ox  t rea t men t f or  migraine  and  chronic  daily
headache  in  adolescen t s . J  Neurosci  Nurs , 2009 . 41(5) : p . 235-[ADDRESS_871669] , Behavioral  and  prophylac t ic  pharmacological
interven t ion  s t udies  o f pedia t ric  migraine : an  explora t ory  me t a-analysis . Pain , 1995 . 60(3) : p . 239-
55.
8.  Hershey , A . D ., e t al ., Childhood  and  Adolescen t Migraine  Preven t ion  (CHAMP)  s t udy : a  double-
blinded , placebo-con t rolled , compara t ive  e ff ec t iveness  s t udy  o f ami t rip t yline , t opi[INVESTIGATOR_649954] t e , and
placebo  in  t he  preven t ion  o f childhood  and  adolescen t migraine . Headache , 2013 . 53(5) : p . 799-
816.
9.  Jacobs , H . and  J . Glads t ein , Pedia t ric  headache : a  clinical  review . Headache , 2012 . 52(2) : p .
333-9 .
10. Kabbouche , M ., H . O ' Brien , and  A . D . Hershey , Onabo t ulinum t oxinA  in  pedia t ric  chronic  daily
headache . Curr  Neurol  Neurosci  Rep , 2012 . 12(2) : p . 114-7 .
11. Kacperski , J . and  A . D . Hershey , Preven t ive  drugs  in  childhood  and  adolescen t migraine . Curr
Pain Headache  Rep , 2014 . 18(6) : p . 422 .
12. Lewis , D . W . and  SpringerLink  (Online  service) , Clinician&#x2019 ; s  Manual  on  Trea t men t o f
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 5 of 29
Pedia t ric  Migraine . 2010 , Springer  Heal t hcare  L t d .: Tarporley .
13.  Mack , K . J ., Managemen t o f chronic  daily  headache  in  children . Exper t Rev  Neuro t her , 2010 .
10(9) : p . 1479-86 .
14. Rober t son , C . E . and  I. Garza , Cri t ical  analysis  o f t he  use  o f onabo t ulinum t oxinA  (bo t ulinum  t oxin
type A)  in  migraine . Neuropsychia t r  Dis  Trea t, 2012 . 8 : p . 35-48 .
15. Schroeder , A . S ., e t al ., Ten-year  f ollow-up  in  a  case  series  o f in t egra t ive  bo t ulinum  t oxin
interven t ion  in  adolescen t s  wi t h  chronic  daily  headache  and  associa t ed  muscle  pain .
Neuropedia t rics , 2012 . 43(6) : p . 339-45 .
16. Seshia , S . S ., Chronic  daily  headache  in  children  and  adolescen t s . Curr  Pain  Headache  Rep ,
2012 . 16(1) : p . 60-72 .
17.  Taj t i , J ., e t al ., Prophylac t ic  Drug  Trea t men t o f Migraine  in  Children  and  Adolescen t s : An  Upda t e .
Curr Pain  Headache  Rep , 2016 . 20(1) : p . 1 .
18. Yonker , M . and  T . Mangum , Migraine  managemen t in  children . Curr  Neurol  Neurosci  Rep , 2015 .
15(5) : p . [ADDRESS_871670] I ON  2:  ROLES  AND  EXPERT I SE  OF  THE  STUDY  TEAM
1. Lis t all  research  t eam  members  who  will  in t erac t or  in t ervene  wi t h  human  subjec t s  or  will  have
access  t o  iden t i f iable  priva t e  in f orma t ion  abou t human  subjec t s . I nclude  addi t ional  rows  f or  Co-
researchers  and  Research  Personnel , as  needed .
2. For  each  research  t eam  member , indica t e  all  applicable  research  ac t ivi t ies  t he  individual  will
perform . Finalizing  in f ormed  consen t is  reviewing , answering / asking  ques t ions , con f irming
compe t ency , as  necessary , and  signing / con f irming  t he  in f ormed  consen t.
3. If applicable , lis t t he  Facul t y  Sponsor  as  a  Co-Researcher  who  will  have  research  oversigh t
responsibili t ies .
Lead  Researcher:
Name  [CONTACT_649968] : Sha li n i Shah , MD
Posit ion / Ti t le  and  Depar t men t: Associa t e  Program  Direc t or , Pain  Medicine  Fellowship  and  an  Assis t an t
Clinical  Pro f essor  in  t he  Depar t men t o f Anes t hesiology  &  Periopera t ive  Care  Division  o f Pain
Managemen t a t UC  I rvine  Heal t h  / UC  I rvine  Heal t h  Cen t er  f or  Comprehensive  Pain  Managemen t, and
Direc t or  o f Pedia t ric  Pain  Medicine  a t UC  I rvine  Heal t h .
Team  Member  will : [  X  ]  Screen / Recrui t [  X  ]  Finalize  I n f ormed  Consen t
[ X ] Per f orm  Research  Ac t ivi t ies  (describe  below) [  X  ]  Access  subjec t iden t i f iable  da t a
List t he  research  ac t ivi t ies / procedures  t o  be  per f ormed  and  t he  individual ’s  relevan t quali f ica t ions
(training , experience) : Dr . Shah’s  du t ies  include : per f orming  inves t iga t ional  s t udy  t rea t men t injec t ions ,
research  procedures , access  t o  iden t i f iable  da t a , da t a  collec t ion , da t a  analysis , and  publica t ion  dra ft ing .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 6 of 29
Co-Researcher:
Name  [CONTACT_649968] : Joseph  R i nehart , MD
Posit ion / Ti t le  and  Depar t men t: Associa t e  Clinical  Pro f essor  and  Vice  Chair  o f Research  in  t he
Depar t men t o f Anes t hesiology  and  Periopera t ive  Care  a t UC  I rvine  Heal t h
Team  Member  will : [  ]  serve  as  Facul t y  Sponsor  wi t h  research  oversigh t responsibili t ies
[ X ]  Screen / Recrui t [  X  ]  Finalize  I n f ormed  Consen t
[ X ]  Per f orm  Research  Ac t ivi t ies  (describe  below) [  X  ]  Access  subjec t iden t i f iable  da t a
List t he  research  ac t ivi t ies / procedures  t o  be  per f ormed  and  t he  individual ’s  relevan t quali f ica t ions
(training , experience) : Dr . Rinehar t ’s  du t ies  include : access  t o  iden t i f iable  da t a , da t a  collec t ion , da t a
analysis , and  publica t ion  dra ft ing .
Research  Personne l :
Name  [CONTACT_649968] : M i chae l -Dav i d  Ca l deron , BS
Posit ion / Ti t le  and  Depar t men t: Clinical  Research  Coordina t or  in  t he  Depar t men t o f Anes t hesiology  and
Periopera t ive  Care  a t UC I Heal t h
Team  Member  will : [  ]  Screen / Recrui t [  ]  Finalize  I n f ormed  Consen t
[ X ] Per f orm  Research  Ac t ivi t ies  (describe  below) [  X  ]  Access  subjec t iden t i f iable  da t a
List t he  research  ac t ivi t ies / procedures  t o  be  per f ormed  and  t he  individual ’s  relevan t quali f ica t ions
(training , experience) : He  will  assis t wi t h  t he  necessary  suppor t t o  coordina t e , develop , implemen t, and
evalua t e  projec t procedures  and  ma t erials . He  has  t wo  plus  years  o f experience  conduc t ing  clinical
research  (including  FDA  regula t ed)  s t udies  as  a  research  coordina t or . He  has  vas t experience  in  da t a
collec t ion  and  da t a  analysis  during  t his  t ime . He  has  been  involved  in  His  du t ies  include : access  t o
ident i f iable  da t a , da t a  collec t ion , da t a  analysis , and  publica t ion  dra ft ing .
Research  Personne l :
Name  [CONTACT_649968] : M i chae l Ma , BS
Posit ion / Ti t le  and  Depar t men t: Clinical  Research  Coordina t or  in  t he  Depar t men t o f Anes t hesiology  and
Periopera t ive  Care  a t UC I Heal t h
Team  Member  will : [  ]  Screen / Recrui t [  ]  Finalize  I n f ormed  Consen t
[ X ] Per f orm  Research  Ac t ivi t ies  (describe  below) [  X  ]  Access  subjec t iden t i f iable  da t a
List t he  research  ac t ivi t ies / procedures  t o  be  per f ormed  and  t he  individual ’s  relevan t quali f ica t ions
(training , experience) : He  will  assis t wi t h  t he  necessary  suppor t t o  coordina t e , develop , implemen t, and
evalua t e  projec t procedures  and  ma t erials . He  has  t wo  plus  years  o f experience  conduc t ing  clinical
research  (including  FDA  regula t ed)  s t udies  as  a  research  coordina t or . He  has  vas t experience  in  da t a
collec t ion  and  da t a  analysis  during  t his  t ime . His  du t ies  include : access  t o  iden t i f iable  da t a , da t a
collec t ion , da t a  analysis , and  publica t ion  dra ft ing .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 7 of 29
Research  Personne l :
Name  [CONTACT_649968] : Pau l ette  Mensah , BA
Posit ion / Ti t le  and  Depar t men t: Clinical  Research  Coordina t or  in  t he  Depar t men t o f Anes t hesiology  and
Periopera t ive  Care  a t UC I Heal t h
Team  Member  will : [  ]  Screen / Recrui t [  ]  Finalize  I n f ormed  Consen t
[ X ] Per f orm  Research  Ac t ivi t ies  (describe  below) [  X  ]  Access  subjec t iden t i f iable  da t a
List t he  research  ac t ivi t ies / procedures  t o  be  per f ormed  and  t he  individual ’s  relevan t quali f ica t ions
(training , experience) : She  will  assis t wi t h  t he  necessary  suppor t t o  coordina t e , develop , implemen t,
and evalua t e  projec t procedures  and  ma t erials . She  has  vas t experience  in  da t a  collec t ion  and  da t a
analysis . Her  du t ies  include : access  t o  iden t i f iable  da t a , da t a  collec t ion , da t a  analysis , and  publica t ion
drafting .
SECT I ON  3:  SUBJECT  POPULAT I ON(S)  ( I ND I V I DUALS / RECORDS / SPEC I MENS)
A. Sub j ects  To  Be  Enro ll ed  on  th i s  UC I protoco l (Persons / Records / B i ospec i mens)
1. Comple t e  t he  t able  o f subjec t enrollmen t s  below . I nclude  addi t ional  rows  f or  subjec t ca t egory / group ,
as needed .
2. If t he  s t udy  involves  t he  use  o f exis t ing  records  or  biological  specimens , speci f y  t he  maximum
number  t o  be  reviewed / collec t ed  and  t he  number  needed  t o  address  t he  research  ques t ion .
Number
Category / Group
(e.g., adul t s , con t rols , paren t s ,
children)
Children / Adolescen t sAge Range
(e.g., 7-12 , 13–17 ,
adult s)
8-17Max i mum  Number
to be  Consented  or
Revi ewed / Co ll ected
(include  wi t hdrawals
and  screen  f ailures)
35Expected  to
Comp l ete  the
Study  or  Needed
to Address  the
Research
Quest i on
26
Tota l :  35
B. Overa ll Study  Samp l e  S i ze
If this  is  a  mul t i-si t e  s t udy , provide  t he  t o t al  number  o f subjec t s  t o  be  enrolled  f rom  all  si t es .
[ X ]  No t applicable : This  s t udy  will  only  t ake  place  a t UC I, and  does  no t involve  o t her  si t es .
Total  number  o f subjec t s  across  all  si t es : <Type  here>
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  [ADDRESS_871671]  a t leas t 15
days  o f repor t ed  headache  during  t his  period , wi t h  a t leas t 4  dis t inc t epi[INVESTIGATOR_649955] t ing  a t leas t 4  hours
each .
Inclus i on  Cr i ter i a
Children  aged  8-17
Medical  his t ory  o f chronic  migraine  f or  a t leas t 6  mon t hs
15  or  more  headache  days  during  a  4  week  period
Exclus i on  cr i ter i a
Previous  use  o f any  bo t ulinum  t oxin  o f any  sero t ype  f or  any  reason
Diagnosis  o f Myas t henia  gravis , Ea t on-Lamber t Syndrome , Amyo t rophic  La t eral  Sclerosis
Trea t men t o f headache  using  acupunc t ure , t ranscu t aneous  elec t rical  s t imula t ion  (TENS) ,
cranial  t rac t ion , den t al  splin t s , or  injec t ion  o f anes t he t ics / s t eroids  wi t hin  4  weeks  prior  t o  t he
week  -4  screening  visi t
Pregnancy
 Hypersensi t ivi t y  t o  any  bo t ulinum  t oxin  prepara t ion  or  t o  any  o f t he  componen t s  in  t he
formula t ion  and  I n f ec t ion  a t t he  proposed  injec t ion  si t e”  or  added  as  “applicable
contraindica t ions  t o  Bo t ox
2. If eligibili t y  is  based  on  age , gender , pregnancy / childbearing  po t en t ial , social / e t hnic  group , or
language  spoken  (e . g ., English  Speakers  only) , provide  a  scien t i f ic  ra t ionale .
[ ] No t applicable : Subjec t eligibili t y  is  no t based  on  t hese  f ac t ors .
Patien t s  who  are  younger  t han  18  years  o f age  are  physiologically  di ff eren t compared  t o  t he  general
popula t ion . His t orically , Bo t ox®  has  been  u t ilized  f or  a  reduc t ion  in  f requency  o f headaches  in  adul t
patien t s  aged  18  or  grea t er  [ 14 . 15 ]. We  are  inves t iga t ing  t he  ou t comes  o f t his  speci f ic  pa t ien t
popula t ion  aged  8-17  years  t o  receive  Bo t ulinum  t oxin  t ype  A  (Bo t ox  ®)  f or  t he  t rea t men t o f
neurological  pain  (migraine , chronic  daily  or  t ension- t ype  headaches) .
SECT I ON  4:  RECRU I TMENT  METHODS
Check  any  o f t he  f ollowing  me t hods  t ha t will  be  used  t o  recrui t subjec t s  f or  t his  s t udy :
[ ] This  s t udy  involves  no  direc t con t ac t wi t h  subjec t s  (i . e ., use  o f exis t ing  records , char t s , specimens) .
Speci f y  da t abase  or  I RB-approved  pro t ocol  number  (HS#) , i f applicable : <Type  here>
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 9 of 29
[ X ] Adver t isemen t s , f lyers , brochures , email , Facebook , and / or  o t her  media .
Speci f y  where  recrui t men t ma t erials  will  be  pos t ed : Subjec t Recrui t men t Flyer  will  be  sen t t o
colleagues  f or  t he  purpose  o f re f erring  individuals / pa t ien t s  in t eres t ed  in  t he  s t udy .
If subjec t s  will  be  recrui t ed  by  [CONTACT_2319] , e-mail , or  phone , speci f y  how  t heir  con t ac t in f orma t ion  will  be
obtained : <Type  here>
Submi t recrui t men t ma t erials  f or  I RB  approval .
[ X ]  The  s t udy  will  be  lis t ed  on  Clinical t rials . gov .  All  clinical  research  mus t be  regis t ered .
[ ] The  s t udy  will  be  lis t ed  on  t he  UC  I rvine  Heal t h  Clinical  Trials  web  page .
Submi t t he  UC I MC  S t andard  Research  Recrui t men t Adver t isemen t f or  I RB  approval .
[ ] The  UC I Social  Sciences  Human  Subjec t s  Lab / Sona  Sys t ems  will  be  used .
Submi t t he  Social  Science  Human  Subjec t Pool  Recrui t men t Adver t isemen t f or  I RB  approval .
[ ] Re f erral  f rom  colleagues
 S t udy  t eam  will  provide  colleagues  wi t h  UC I I RB-approved  recrui t men t ma t erials  f or
distribu t ion  t o  po t en t ial  subjec t s  (e . g ., recrui t men t f lyer , in t roduc t ory  le tt er) ;
 An  I RB-approved  recrui t men t le tt er  will  be  sen t by  t he  t rea t ing  physician .  The  le tt er  will  be
signed  by  t he  t rea t ing  physician  and  sen t t o  his / her  pa t ien t s  t o  in f orm  t hem  abou t how  t o
contac t s t udy  t eam  members ; and / or
 Colleagues  ob t ain  permission  f rom  in t eres t ed  pa t ien t t o  release  con t ac t in f orma t ion  t o
researchers .
S t udy  t eam  does  no t have  access  t o  pa t ien t names  and  addresses  f or  mailing .
 If colleagues  will  screen  t heir  pa t ien t s’  medical  records  t o  de t ermine  subjec t eligibili t y  and
approach  pa t ien t s  direc t ly  abou t s t udy  par t icipa t ion : Comple t e  Appendix  T  t o  reques t a
partial  waiver  o f H I PAA  Au t horiza t ion .
Submi t recrui t men t ma t erials  f or  I RB  approval .
[ ] S t udy  t eam  will  con t ac t po t en t ial  subjec t s  who  have  given  prior  permission  t o  be  con t ac t ed  f or
research  s t udies .
Speci f y  when  and  how  t hese  individuals  gran t ed  permission  f or  f u t ure  con t ac t: <Type  here>
Speci f y  da t abase  or  I RB-approved  pro t ocol  number  (HS#) : <Type  here>
[ ] S t udy  t eam  members  will  approach  t heir  own  pa t ien t s , s t uden t s , employees  f or  par t icipa t ion  in  t he
study .
[ X ]  S t udy  t eam  will  screen  UC I MC  medical  records  t o  which  t hey  have  access  t o  de t ermine  subjec t
eligibili t y . The  pa t ien t s’  physicians  will  approach  pa t ien t s  direc t ly  abou t s t udy  par t icipa t ion .
Comple t e  Appendix  T  t o  reques t a  par t ial  waiver  o f H I PAA  Au t horiza t ion .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 0 of 29
[ ] O t her  Recrui t men t Me t hods : < I ndica t e  t he  recrui t men t me t hod(s)  here>
SECT I ON  5:  I NFORMED  CONSENT  PROCESS
A. Methods  of  I nformed  Consent
1. Indica t e  all  applicable  in f ormed  consen t me t hods  f or  t his  s t udy . Submi t t he  consen t/ assen t
documen t (s)  wi t h  your  e- I RB  Applica t ion  (e . g ., S t udy  I n f orma t ion  Shee t, Recrui t men t scrip t,
Consen t Form , e t c . ) . Only  I RB  approved  consen t f orms  (con t aining  t he  I RB  approval  f oo t er)  may
be used  t o  consen t human  subjec t s  a t UC I.
[ X ]  Wr i tten  (s i gned)  i nformed  consent  w ill be  obta i ned  from  sub j ects . Signed  in f ormed
consen t, paren t al  permission , and / or  child  assen t will  be  ob t ained  f rom  subjec t s , as  applicable .
[ ] Request i ng  a  wa i ver  of  wr i tten  (s i gned)  i nformed  consent . Signed  consen t will  no t be
obtained ; consen t will  be  ob t ained  verbally  or  via  t he  web . I n f ormed  consen t, paren t al  permission
and/or  child  assen t will  be  ob t ained  f rom  subjec t s , as  applicable .
Comple t e  Appendix  P .
[ ] Request i ng  to  seek  surrogate  consent  from  a  l ega ll y  author i zed  i nd i v i dua l. Surroga t e
consen t may  be  considered  only  in  research  s t udies  rela t ing  t o  t he  cogni t ive  impairmen t, lack  o f
capaci t y  or  serious  or  li f e- t hrea t ening  disease  and  condi t ions  o f t he  research  subjec t s .
Comple t e  Appendix  E .
[ ] Request i ng  a  wa i ver  of  i nformed  consent . (i . e ., consen t will  no t be  ob t ained) . Skip  t o  Sec t ion
5.B.
Comple t e  Appendix  O .
2. Indica t e  where  t he  consen t process  will  t ake  place .
[ X ]  I n  a  priva t e  room
[ ] In  a  wai t ing  room
[ ] In  an  open  uni t
[ ] In  a  group  se tt ing
[ ] The  in t erne t
[ ] I n  public  se tt ing
[ ] Over  t he  phone
[ ] O t her  (speci f y) : <Type  here>
3. Speci f y  how  t he  research  t eam  will  assure  t ha t subjec t s  have  su ff icien t t ime  t o  consider  whe t her  t o
participa t e  in  t he  research .
[ ] Subjec t s  will  be  allowed  t o  t ake  home  t he  unsigned  consen t f orm  f or  review  prior  t o  signing  i t.
[ ] Subjec t s  will  be  allowed  <Type  here>  hours  t o  consider  whe t her  t o  consen t.
[ X ]  O t her  (speci f y) : We  will  avoid  coercion  by  [CONTACT_649961]  t ha t par t icipa t ion  is  comple t ely  volun t ary .
Whet her  or  no t t he  pa t ien t chooses  t o  par t icipa t e  will  no t a ff ec t t he  care  t ha t t hey  would  receive . We  will
use a  priva t e  room  t o  ob t ain  consen t and  t he  pa t ien t will  be  given  adequa t e  t ime  t o  decide  i f t hey  would
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 1 of 29
like to  par t icipa t e . We  are  reques t ing  t o  consen t t he  subjec t s  on  t he  day  o f t heir  visi t since  we  do  no t
anticipa t e  t ha t t he  s t udy  will  cause  addi t ional  s t ress  t o  t he  subjec t s .
4. If children  are  enrolled  in  t his  s t udy , describe  t he  paren t al  permission  process  and  t he  child  assen t
process .
[ ] No t applicable : Children  are  no t enrolled  in  t his  s t udy .
The s t udy  inves t iga t or  will  explain  t he  s t udy  in  de t ail  t o  t he  paren t s  and  child  t o  answer  any  ques t ions
that t hey  may  have . The  research  t eam  will  emphasize  con f iden t iali t y  and  righ t s  o f s t udy  subjec t s
when  ob t aining  consen t. The  pa t ien t will  be  enrolled  in  t he  s t udy  only  a ft er  a t leas t one  o f t he
inves t iga t ors  reviews  t he  consen t f orm  wi t h  t he  pa t ien t, ensuring  t ha t t he  pa t ien t unders t ands  t he
study . All  ques t ions  will  be  answered  and  wri tt en  consen t ob t ained .
5. Some  subjec t s  may  be  vulnerable  t o  coercion  or  undue  in f luence , such  as  t hose  who  are
economically  or  educa t ionally  disadvan t aged , men t ally  disabled , or  s t uden t s  (undergradua t e ,
gradua t e , and  medical  s t uden t s)  and  employees  o f UC I (adminis t ra t ive , clerical , nursing , lab
technicians , pos t -doc t oral  f ellows  and  house  s t a ff, e t c . ) , describe  t he  procedures  t o  ensure  t he
volun t ary  par t icipa t ion  o f t hese  individuals .
[ ] No t applicable : Subjec t s  are  no t vulnerable  t o  coercion  or  undue  in f luence .
[ X ]  O t her  (speci f y) : The  s t udy  t eam  will  make  every  e ff or t t o  minimize  undue  in f luence . Procedures
to ensure  volun t ary  par t icipa t ion  includes : allowing  t he  subjec t adequa t e  t ime  during  t he  consen t
process . We  will  only  disclose  t he  de t ails  o f t he  s t udies  in  a  priva t e  room . No  member  o f t he  s t udy
team  has  any  disclosable  con f lic t s  o f in t eres t s . All  subjec t s  will  be  encouraged  t o  discuss  s t udy
participa t ion  wi t h  f amily  and  f riends  be f ore  consen t ing . No  ma tt er  wha t t he  pa t ien t will  decide
regarding  par t icipa t ion , pa t ien t care  received  f rom  t heir  physician  will  no t be  a ff ec t ed .
B. Hea l th  I nsurance  Portab ili ty  and  Accountab ili ty  Act  (H I PAA)  Author i zat i on
Indica t e  all  applicable  H I PAA  au t horiza t ion  me t hods  f or  t his  s t udy .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 2 of 29
[ ] No t applicable : S t udy  does  no t involve  t he  crea t ion , use , or  disclosure  o f Pro t ec t ed  or  Personal
Healt h  I n f orma t ion  (PH I ) .
[ ] Request i ng  a  Tota l wa i ver  of  H I PAA  Author i zat i on . H I PAA  au t horiza t ion  will  no t be  ob t ained  a t
all for  t he  s t udy .
Comple t e  Appendix  T .
[ X ]  Request i ng  a  Part i a l wa i ver  of  H I PAA  Author i zat i on . H I PAA  au t horiza t ion  will  no t be  ob t ained
for screening / recrui t men t purposes . However , wri tt en  (signed)  H I PAA  research  au t horiza t ion  is
obtained  f or  f ur t her  access  t o  personal  heal t h  in f orma t ion .
Comple t e  Appendix  T .
[ X ] Wr i tten  (s i gned)  H I PAA  Research  Author i zat i on  w ill be  obta i ned  from  sub j ects . Signed
authoriza t ion , paren t al  au t horiza t ion , and / or  child  assen t will  be  ob t ained  f rom  subjec t s , as
applicable .
Comple t e  t he  H I PAA  Research  Au t horiza t ion  f orm .
C. Methods  of  I nformed  Consent  for  non-Eng li sh  Speakers
1. Indica t e  t he  applicable  in f ormed  consen t me t hod  f or  non-English  speakers .
[ ] No t applicable : Only  individuals  who  can  read  and  speak  English  are  eligible  f or  t his  s t udy .
Scien t i f ic  jus t i f ica t ion  mus t be  provided  in  Sec t ion  3 . C . 2 .
[ X ] The  English  version  o f t he  consen t f orm  will  be  t ransla t ed  in t o  appropria t e  languages  f or  non-
English  speaking  subjec t s  once  I RB  approval  is  gran t ed . The  t ransla t ed  consen t f orm  mus t be
submi tt ed  t o  t he  I RB  f or  review  prior  t o  use  wi t h  human  subjec t s . Only  I RB  approved  consen t
forms  (con t aining  t he  I RB  approval  s t amp)  may  be  used  t o  consen t human  subjec t s  a t UC I.
[ ] Reques t ing  a  shor t f orm  consen t process .
Comple t e  Appendix  Q .
The shor t f orm  process  will  be  used  f or  t he  f ollowing  occasional  and  unexpec t ed  languages : [
] All non-English  languages
[ ] All  non-English  languages  excep t Spanish
[ ] O t her  languages  (speci f y) : <Type  here>
2. Explain  how  non-English  speaking  subjec t s  will  be  consen t ed  in  t heir  language  and  who  will  be
responsible  f or  in t erpre t ing  and  f acili t a t ing  t he  in f ormed  consen t discussion  f or  t he  non-English
speaking  subjec t s .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 3 of 29
[ ] A t leas t one  member  o f t he  s t udy  t eam  is  f luen t in  t he  language  t ha t will  be  used  f or
communica t ion , and  t ha t s t udy  t eam  member(s)  will  be  available  during  emergencies .
For all  members  o f t he  s t udy  t eam  responsible  f or  ob t aining  in f ormed  consen t f rom  non-
English  speaking  subjec t s , provide  t heir  quali f ica t ions  t o  serve  in  t his  capaci t y  (i . e . language
fluency)  in  Sec t ion  2 .
[ X ]  The  s t udy  t eam  has  24-hour  access  t o  a  t ransla t ion  service  wi t h  su ff icien t medical  exper t ise  t o
discuss  t he  research  in  t his  s t udy .
[ ] O t her  (explain) : <Type  here>
SECT I ON  6 :  RESEARCH  METHODOLOGY / STUDY  PROCEDURES
A. Study  Locat i on
Speci f y  where  t he  research  procedures  will  t ake  place  (e . g . UC I Douglas  Hospi t al  –  Cardiac  Care  Uni t,
UCI Main  Campus  Hewi tt Hall , UC I Heal t h  –  Pavilion  II, UC I Family  Heal t h  Cen t er , Anaheim , I rvine  High
School) .
If research  ac t ivi t ies  will  also  be  conduc t ed  a t non-UC I loca t ions  (e . g ., educa t ional  ins t i t u t ions ,
businesses , organiza t ions , e t c . ) , Comple t e  Appendix  A . Le tt ers  o f Permission  or  o t her  documen t a t ion
may be  required  (e . g . O ff -si t e  Research  Agreemen t s  or  I RB  Au t horiza t ion  Agreemen t s) .
The research  procedures  will  t ake  place  a t UC  I rvine  Medical  Cen t er  in  t he  Medical  Special t ies  f acili t y
and Go tt schalk  Medical  Plaza  on  UC I main  campus . Any  da t a  ob t ained  f or  t he  s t udy  will  be  s t ored  in  a
secure , locked  f acili t y  in  t he  UC I Anes t hesia  Research  Depar t men t f or  t he  dura t ion  o f t he  s t udy .
B. Study  Des i gn
1. Include  an  explana t ion  o f t he  s t udy  design  (e . g ., randomized  placebo-con t rolled , cross-over , cross-
sectional , longi t udinal , e t c . )  and , i f appropria t e , describe  s t ra t i f ica t ion / randomiza t ion / blinding
scheme .
Study  Pro t ocol
After  enrollmen t, each  subjec t will  begin  wi t h  a  28  day  baseline  screening  phase  f ollowed  by  a  24  week
double-blind , placebo-con t rolled , randomized  AB | BA  crossover  period  as  t he  primary  s t udy  pro t ocol ,
followed  by  a  second  24-week  open-label  period  where  all  subjec t s  will  receive  t rea t men t wi t h
Onabo t ulinum t oxinA  as  f ollow-on  t rea t men t. There  will  be  one  t rea t men t every  12  weeks , meaning  4
treatmen t blocks  over  t he  48  week  s t udy  period  t o t al . Those  assigned  t o  t he  AB  group  will  receive
Onabo t ulinum t oxinA  in  t he  f irs t t rea t men t and  saline  placebo  in  t he  second , while  t hose  in  t he  BA  group
will receive  saline  and  t hen  Onabo t ulinum t oxinA . Bo t h  groups  will  t hen  receive  Onabo t ulinum t oxinA  in
the las t t wo  t rea t men t s . Progress  check-ups  will  occur  every  6  weeks  during  t he  s t udy . Twelve  week
blocks  were  speci f ically  selec t ed  in  order  t o  minimize  carry-over  e ff ec t s  f rom  t rea t men t periods , as  t he
clinical  e ff icacy  o f Onabo t ulinum t oxinA  is  nearly  gone  a ft er  t welve  weeks  in  t he  P I ’s  experience  and
repor t ed  li t era t ure .
Randomiza t ion  will  be  via  selec t ion  o f sealed  envelope . I njec t ions  will  be  per f ormed  a t f ixed-si t e , f ixed-
dose  loca t ions  a t 31  si t es  recommended  by  t he  PREEMPT  1  and  2  s t udies , including  procerus ,
corruga t ors , f ron t alis , t emporalis , occipi t alis , splenius  capi t is , and  t rapezius  muscle  beds . A t t he
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 4 of 29
inves t iga t or’s  discre t ion , an  addi t ional  40U  may  be  adminis t ered  using  a  f ollow- t he-pain  s t ra t egy . The
maximum  dose  will  be  155  U  across  31  s i tes . All  t rea t men t s  will  be  per f ormed  by  t he  P I.
2. Provide  precise  de f ini t ions  o f t he  s t udy  endpoin t s  and  cri t eria  f or  evalua t ion ; i f t he  primary  ou t comes
are derived  f rom  several  measuremen t s  (i . e ., composi t e  variables)  or  i f endpoin t s  are  based
composi t e  variables , t hen  describe  precisely  how  t he  composi t e  variables  are  derived .
Primary  outcome  var i ab l es:
 Pain  scores : as  a  s t andard  par t o f t he  procedure , pa t ien t s  are  asked  t o  record  t heir  pain  scores
before  and  a ft er  t heir  procedure . The  principal  endpoin t s  are  in t ensi t y  on  a  10  poin t NRS  scale
(VAS  where  needed) , and  f requency  o f migraine  epi[INVESTIGATOR_211101]  a  30  day  period . This  will  be
compared  t o  baseline  da t a  pre-injec t ion . For  t he  s t udy , pain  score  da t a  will  be  collec t ed  up  un t il
the las t f ollow  up  o f t he  las t injec t ion  o f each  pa t ien t s’  Bo t ox  ®  injec t ion  series .
 Dura t ion  o f bene f i t f rom  t he  Bo t ox  ®  injec t ions : reduc t ion  in  pain  score  by  [CONTACT_649962] t er  t han  or  equal  t o
30%
 Func t ionali t y : t he  ex t en t o f normal  ac t ivi t y  able  t o  be  per f ormed  by  a  pa t ien t
 Disabili t y : inabili t y  t o  f unc t ion  normally , physically  or  men t ally
 Opi[INVESTIGATOR_649956] t ion : amoun t o f opi[INVESTIGATOR_649957] t ion  consumed
 Neuropa t hic / migraine  medica t ion  consumed  including  immedia t e  release  NSA I D
Secondary  outcome  var i ab l es:
 Quali t y  o f pain : con t inuous , in t ermi tt en t, t hrobbing , e t c .
 Associa t ed  side  e ff ec t s : nausea , vomi t ing , f ood  in t ake , diarrhea , cons t ipa t ion , anxie t y , depression
and/or  adverse  even t s  associa t ed  wi t h  s t udy  drug
 Psychological  his t ory  i . e . anxie t y , depression
 Neuropa t hy : any  weakness , numbness , and  pain  f rom  nerve  damage , usually  in  t he  hands  and
feet
 Type  o f analgesia / anes t hesia : analgesic / anes t he t ic  medica t ion(s)  used  during  procedure  
Incidence  o f hospi t al  admissions
 Incidence  o f ER  visi t s
 Curren t medica t ion  use
Other  var i ab l es:
 Neurological  workup : Neurological  medical  evalua t ion , including  medical  his t ory , physical
examina t ion , medical  t es t s , survey  o f t he  pa t ien t ’s  medical  record  f or  any  in f orma t ion  regarding
Neurological  disease
 Diagnosis : iden t i f ica t ion  o f chronic  migraine  head  pain
 Indica t ions : reason  f or  Bo t ox  ®  injec t ions , number  o f injec t ions  in  t he  Bo t ox  ®  injec t ion  series  
 Procedure : speci f ic  procedure  including  loca t ion  o f procedure , imaging  in f orma t ion , and  o t her
speci f ic  procedure  in f orma t ion
 Block  medica t ions : medica t ions  and  dosage  used  f or  t he  Bo t ox  ®  injec t ions
 Disposi t ion : no t es  regarding  pa t ien t ’s  s t a t e  during  procedure
C. Research  Procedures
1. Provide  a  de t ailed  chronological  descrip t ion  o f all  research  procedures .
Methods
Given  t he  exis t ing  evidence  o f e ff icacy  in  t he  available  scien t i f ic  da t a  (adul t and  re t rospec t ive  pedia t ric)
and t he  P I ’s  ex t ensive  personal  experience  in  t he  pedia t ric  popula t ion  (where  use  o f t he  s t udy  drug  has
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 5 of 29
been  f ound  t o  be  t rans f orma t ive) , prolonged  wi t hholding  o f Onabo t ulinum t oxinA  f or  t he  purpose  o f s t udy
was no t considered  reasonable  by  t he  P I. Thus , a  s t udy  design  minimizing  t he  placebo  con t rol  period
while  s t ill  allowing  f or  comparison  o f Onabo t ulinum t oxinA  t o  a  con t rol  group , was  desirable . An  AB | BA
cross-over  design  (which  uses  each  pa t ien t has  his / her  own  con t rol , bo t h  minimizing  recrui t men t numbers
and t he  need  f or  a  con t rol  group  which  never  receives  t rea t men t wi t h  Onabo t ulinum t oxinA) , was  selec t ed
as the  bes t op t ion  a ft er  consul t a t ion . The  in f luence  o f con f ounding  covaria t es  is  reduced  because  each
crossover  pa t ien t serves  as  his  or  her  own  con t rol . A  f our  week  baseline  prior  t o  t rea t men t will  ac t as  a  no-
treatmen t con t rol  t o  compare  t o  bo t h  t he  t rea t men t and  placebo . The  s t udy  does  no t exclude  pa t ien t s  on
preven t ive  or  abor t ive  migraine  medica t ion , in  an  a tt emp t t o  demons t ra t e  superiori t y  on  s t udy  drug  over
conserva t ive  medical  managemen t.
15 Days  of  r epo rt ed
headache  wi t h  a t
leas t  4  dis t inc t
epi[INVESTIGATOR_1841] ,  4  hou r s
 eachGroup  1:
Botox®Group  1:
PlaceboLegend
Follow‐up  visi t
Injec t ion  p r ocedu r e
Group  1  &  Group  2:
Botox®  and/or  conservative
management
E
N
R
O
L
L
M
E
N
T‐ 28 Days
|WEEKS|Group  2:
Placebo
0 6Group  2:
Botox®
12 18 24 30 36 42 48
Double‐blind, placebo controlled, randomized
AB|BA CrossoverOpen‐Label Period
Diagrams  1-4 : Recommended  I njec t ion  Si t es  (A  t hrough  G)  f or  Chronic  Migraine
(From  BOTOX®  Prescribing  I n f orma t ion)  To t al  o f [ADDRESS_871672] . Paren t/ guardian  and / or  child  will  sign  an  in f ormed  consen t and  assen t (child)
approving  enrollmen t in  s t udy .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 6 of 29
Patien t Popula t ion
Children  aged  8  –  17  years  o f age  wi t h  a  his t ory  o f migraine  mee t ing  t he  cri t eria  es t ablished  in  I CHD- II
(2004) , Sec t ion  1 . Pa t ien t s  will  provide  a t leas t 28-days  (4  week)  baseline  da t a  in  t he  f orm  a  daily  diary
and mus t have  a t leas t 15  days  o f repor t ed  headache  during  t his  period , wi t h  a t leas t 4  dis t inc t epi[INVESTIGATOR_649958]  a t leas t 4  hours  each . (Pa t ien t s  wi t h  con t inuous  headache  will  t hus  be  excluded  as  t his  may
represen t non-migraine  symp t oms) . A  t o t al  o f 26  pa t ien t s  will  be  enrolled .
Data  Collec t ion
Our primary  endpoin t will  be  t he  same  as  t ha t used  in  t he  PREEMPT  t rials  which  examined  t he  e ff icacy
of Onabo t ulinum t oxinA  in  adul t pa t ien t s  aged  18  or  grea t er  [ 14 , 15 ] Speci f ically , we  will  look  f or  a
reduc t ion  in  f requency  o f headache  days  per  mon t h . I n  t ha t t rial , a t baseline , pa t ien t s  repor t ed  19 . 9  ±
3.6 headache  days  per  mon t h . The  t rea t men t group  showed  a  reduc t ion  o f 8 . 4  days , and  t he  placebo
group  a  reduc t ion  o f 6 . 6  days  (s t andard  devia t ions  on  t hese  reduc t ions  were  no t repor t ed) . I n t erpre t a t ion
of the  da t a  was  complica t ed  by  t he  varied  medica t ion  regimens  t he  pa t ien t s  were  on  a t baseline  (which
frequen t ly  included  over-use  o f opi[INVESTIGATOR_649957] t ions) .
In 1999  t he  Migraine  Disabili t y  Score  (M I DAS)  was  developed  by  S t ewar t e t al . [ 10 ] which  is  an  easy- t o
use 5  i t em  ques t ionnaire  accep t ed  as  a  means  t o  diagnose  and  f ollow  adul t headache . Hershey  e t al
developed  t he  pediM I DAS  based  on  M I DAS  bu t u t ilizes  6  ques t ions , 3  addressing  school  a tt endance
and f unc t ioning , and  3  evalua t ing  par t icipa t ion  in  even t s  ou t side  o f school . [ 22 ]. The  ques t ionnaire  is
based  on  t he  pa t ien t ’s  recall  o f previous  3  mon t hs  and  can  be  used  longi t udinally  t o  asses  response . [ 1 ]
In the  clinical  se tt ing , t he  PedM I DAS  can  be  help f ul  in  assessing  a  pa t ien t' s  migraine  burden  and
response  t o  t herapy . Some  researchers  advoca t e  i t s  use  as  an  ou t come  measure  in  clinical  t rials . The
Pedia t ric  Migraine  Disabili t y  Assessmen t (PedM I DAS)  is  t he  only  valida t ed  clinical  t ool  available  t o
estima t e  migraine  disabili t y  in  t he  school-aged  child , aged  4-18 . [ 22 ]
Each  da t a  poin t will  be  collec t ed  a t baseline , 6  weeks , 12  weeks , 18  weeks , 24  weeks , 30  weeks , 36
weeks , 42  weeks , and  48  weeks
2. Describe  t he  dura t ion  o f a  subjec t ’s  par t icipa t ion  in  t he  s t udy . If t here  are  sub-s t udies , include
durat ion  o f par t icipa t ion  in  each  sub-s t udy .
After  enrollmen t, each  subjec t will  begin  wi t h  a  28  day  baseline  screening  phase  f ollowed  by  a  24  week
double-blind , placebo-con t rolled , randomized  AB | BA  crossover  period , f ollowed  by  a  second  24-week
open-label  period  where  all  subjec t s  will  receive  t rea t men t wi t h  Onabo t ulinum t oxinA . There  will  be  one
treatmen t a t t he  beginning  o f each  12  week  block , meaning  4  t rea t men t s  over  t he  48  week  s t udy  period
total. Those  assigned  t o  t he  AB  group  will  receive  Onabo t ulinum t oxinA  in  t he  f irs t t rea t men t and  saline
placebo  in  t he  second , t hose  in  t he  BA  group  will  receive  saline  and  t hen  Onabo t ulinum t oxinA . Bo t h
groups  will  t hen  receive  Onabo t ulinum t oxinA  in  t he  las t t wo  t rea t men t s . Progress  check-ups  will  occur
every  6  weeks  during  t he  s t udy ; par t icipan t s  will  be  asked  t o  comple t e  t he  Pedia t ric  Migraine  Disabili t y
Assessmen t (PedM I DAS)  survey .
3. Lis t da t a  collec t ion  ins t rumen t s  (e . g ., measures , ques t ionnaires , in t erview  ques t ions , observa t ional
tool, e t c . ) .
Inves t iga t or-au t hored , non-s t andardized , or  un-valida t ed  measures  mus t be  submi tt ed  f or
review .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  [ADDRESS_871673]  t he  f requency  and  in t ensi t y  o f any  neurological  pain  t ha t occurs  f or  t he  dura t ion  o f t he
study . Progress  check-ups  will  occur  every  6  weeks  during  t he  s t udy ; par t icipan t s  will  be  asked  t o
comple t e  t he  Pedia t ric  Migraine  Disabili t y  Assessmen t (PedM I DAS)  survey .
D. UC I MC  Supp l ementary  C li n i ca l Serv i ces
If a UC I MC  clinical  uni t/ depar t men t (e . g ., phlebo t omy  f or  blood  draws , pharmacy  f or  dispensing  s t udy
drug(s) , radia t ion  services  f or  X-rays , MR I s , CT  scans , and  Neurology  f or  lumbar  punc t ures)  will  per f orm
research-rela t ed  procedures :
1. Lis t t he  research  procedure  (e . g . lumbar  punc t ure , MR I, CT  Scan) , and
2. Iden t i f y  t he  uni t/ depar t men t t ha t will  per f orm  t he  procedure .
[ X ]  No t applicable : This  s t udy  does  no t involve  t he  services  o f a  UC I MC  clinical  uni t/ depar t men t.
E. Pr i vacy
Privacy  is  abou t t he  subjec t ’s  abili t y  t o  con t rol  how  much  o t hers  see , t ouch , or  collec t in f orma t ion  abou t
the subjec t. I ndica t e  all  o f t he  f ollowing  me t hods  t ha t will  be  used  t o  assure  subjec t privacy . Viola t ions
of privacy  include  accessing  a  subjec t ’s  priva t e  in f orma t ion  wi t hou t consen t, asking  personal  sensi t ive
informa t ion  in  a  public  se tt ing , being  audio  recorded  or  pho t ographed  wi t hou t consen t.
[ ] Research  procedures  (including  recrui t men t )  are  conduc t ed  in  a  priva t e  room .
[ ] Use  o f drapes  or  o t her  barriers  f or  subjec t s  who  are  required  t o  disrobe .
[ X ]  Only  sensi t ive  in f orma t ion  direc t ly  rela t ed  t o  t he  research  is  collec t ed  abou t subjec t s .
[ ] When  in f orma t ion  is  collec t ed  f rom  in t erne t sources , t he  in t erne t si t e’s  privacy  s t a t emen t will  be
reviewed  and  f ollowed .
Provide  a  copy  o f t he  Da t a  Use  Policy  t o  t he  I RB .
[ ] O t her  (speci f y) : <Type  here>
F. Use  of  Ex i st i ng  B i o l og i ca l Spec i mens  and / or  Ex i st i ng  I nformat i on / Data
1. For  s t udies  t ha t involve  use  o f exis t ing  (i . e . on  t he  shel f; curren t ly  available)  specimens :
a. Indica t e  t he  source  o f t he  specimens  and  whe t her  t he  specimens  were  originally  collec t ed  f or
research  purposes .
b. Explain  how  t he  exis t ing  specimens  will  be  ob t ained .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 8 of 29
[ X ]  No t applicable : This  s t udy  does  no t involve  use  o f exis t ing  biological  specimens .
Source:  I nd i cate  a ll  that  app l y:
[ ] UC I/ UC I MC
Originally  collec t ed  f or  research  purposes : [
[] YES ; UC I I RB  number  (i . e . HS#) : <Type  here>
] NO ; explain : <Type  here>
[ ] UC I MC  Pa t hology  Bioreposi t ory  will  provide  specimens .
[ ] Non-UC I En t i t y ; speci f y : <Type  here>
Originally  collec t ed  f or  research  purposes : [  ]  YES
Submi t a  copy  o f t he  I RB  Approval  No t ice  and
Consen t Form  f or  t he  original  collec t ion .
[ ] NO ; explain : <Type  here>
[ ] O t her ; explain : <Type  here>
2. For  s t udies  t ha t involve  use  o f exis t ing  (i . e . on  t he  shel f; curren t ly  available)  clinical  da t a :
a. Speci f y  t he  source  o f t he  clinical  da t a .
b. Explain  how  t he  s t udy  t eam  will  access  t he  clinical  da t a . Access  t o  UC I Medical  Cen t er  medical
records  f or  research  purposes  ou t side  t he  capaci t y  o f t he  Hones t Broker  Services , such  as
access  t o  physician  no t es , mus t be  ob t ained  f rom  t he  Heal t h  I n f orma t ion  Managemen t
Services .
For inves t iga t or  ini t ia t ed / au t hored  s t udies  only ,  submi t a  da t a  abs t rac t ion  shee t t ha t includes  a
comple t e  lis t o f da t a  elemen t s / in f orma t ion  t ha t will  be  collec t ed  f rom  (exis t ing)  records  or  submi t t he
case  repor t f orm  (CRF ; eCRF) .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 1 9 of 29
[ ] No t applicable : This  s t udy  does  no t involve  use  o f exis t ing  clinical  da t a . Skip  t o  Sec t ion  6 . G .
Source:  I nd i cate  a ll  that  app l y:
[ X ] UC I/ UC I MC .
[] non-UC I En t i t y ; speci f y : <Type  here>
How  Obta i ned:  I nd i cate  a ll  that  app l y:
[ X ] The  s t udy  t eam  will  reques t speci f ic  pa t ien t in f orma t ion / da t a  f rom  UC I MC  Heal t h  I n f orma t ion
Managemen t Services .
[ X ] The  s t udy  t eam  will  review  t heir  pa t ien t s’  records  and  abs t rac t da t a  direc t ly  f rom  t hose  records .
[] The  s t udy  t eam  will  reques t speci f ic  pa t ien t in f orma t ion / da t a  f rom  UC I Heal t h  Hones t Broker
Services . Describe  t he  f ollowing :
Cohor t selec t ion  cri t eria  (e . g ., use  t he  available  Clinical  Terms  f rom  t he  Cohor t Discovery  Tool
such  as  Demographics : Gender , Diagnoses : As t hma , Procedures : Opera t ions  on  diges t ive
system) : <Type  here>
Expec t ed  cohor t size / pa t ien t coun t: <Type  here>
Cohor t a tt ribu t es  or  da t a  elemen t s  (e . g ., lab  t es t values , medica t ion , e t c . ) : <Type  here>
[ ] O t her ; explain : <Type  here>
3. For  s t udies  t ha t involve  use  o f exis t ing  (i . e . on  t he  shel f; curren t ly  available)  clinical  da t a , speci f y  t he
time f rame  o f t he  clinical  da t a  t o  be  accessed  (e . g . records  f rom  January  2002  t o  ini t ial  I RB
approval) .
Exist ing  medical  records  are  checked  f or  t he  dura t ion  o f t he  s t udy .
G. Co ll ect i on  of  Photographs , or  Aud i o / V i deo  Record i ng
1. Describe  all  procedures  involving  t he  use  and / or  collec t ion  o f pho t ographs , or  audio / video  recording .
[ X ]  No t applicable : This  s t udy  does  no t involve  pho t ographs  or  audio / video  recording . Skip  t o
Section  6 . H .
2. Speci f y  i f pho t ographs  or  audio / video  recording  will  include  subjec t iden t i f iable  in f orma t ion  (e . g .,
name , f acial  image) . If so , indica t e  which  iden t i f iers  will  be  collec t ed .
N/A
3. Explain  whe t her  t he  pho t ographs  or  audio / video  recording  will  be  included  in  subsequen t
presen t a t ions  and / or  publica t ions  and , i f so , whe t her  subjec t iden t i f iers  will  be  included .
N/A
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 0 of 29
H. Shar i ng  Resu l ts  w i th  Sub j ects
1. Describe  whe t her  individual  resul t s  (resul t s  o f inves t iga t ional  diagnos t ic  t es t s , gene t ic  t es t s , or
inciden t al  f indings)  will  be  shared  wi t h  subjec t or  o t hers  (e . g ., t he  subjec t ’s  primary  care
physician) . Only  t es t s  ordered  by  a  physician  and  conduc t ed  in  a  CL I A  cer t i f ied  lab  may  be
shared .
2. Explain  wha t in f orma t ion  will  be  shared  and  how  t he  resul t s  will  be  shared .
[ X ]  No t applicable : I ndividual  resul t s  will  no t be  shared  wi t h  subjec t s .
3. Describe  whe t her  overall  s t udy  resul t s  will  be  shared  wi t h  subjec t s .
4. Explain  how  resul t s  will  be  shared .
[ X ]  No t applicable : Final  s t udy  resul t s  will  no t be  shared  wi t h  subjec t s .
I. Stat i st i ca l Cons i derat i ons  (This  sec t ion  is  required  f or  I nves t iga t or-Au t hored  Research)
1. S t a t is t ical  Analysis  Plan : Describe  t he  s t a t is t ical  me t hod(s)  f or  t he  s t a t ed  speci f ic  aims  and
hypo t heses . Your  analysis  plans  should  ma t ch  t he  s t a t ed  s t udy  speci f ic  aims  and  hypo t heses  in
Section  1 .
1. [ ]  No t applicable : A  s t a t is t ical  analysis  plan  is  no t appropria t e  f or  t his  quali t a t ive  s t udy  design . Plan
for assessing  s t udy  resul t s :
Our primary  endpoin t will  be  t he  same  as  t ha t used  in  t he  PREEMPT  t rial  which  examined  t he  e ff icacy
of Onabo t ulinum t oxinA  in  adul t pa t ien t s  [ 1 , 2 ]. Speci f ically , we  will  look  f or  a  reduc t ion  in  f requency  o f
headache  days  per  mon t h , as  well  as  decrease  in  in t ensi t y  u t ilizing  a  10  poin t NRS  scale  (VAS  when
appropria t e) . I n  t ha t t rial , a t baseline , pa t ien t s  repor t ed  19 . 9  ± 3 . 6  headache  days  per  mon t h . The
treatmen t group  showed  a  reduc t ion  o f 8 . 4  days , and  t he  placebo  group  a  reduc t ion  o f 6 . 6  days
(standard  devia t ions  on  t hese  reduc t ions  were  no t repor t ed) . I n t erpre t a t ion  o f t he  da t a  was
complica t ed  by  t he  medica t ion  regimens  t he  pa t ien t s  were  on  a t baseline  (which  f requen t ly  included
over-use  o f opi[INVESTIGATOR_649957] t ions) .
2. Describe  t he  primary  s t a t is t ical  me t hod(s)  t ha t will  be  used  t o  analyze  t he  primary  ou t come(s)  or
endpoin t s .
Design  considera t ions : Given  t he  evidence  o f e ff icacy  in  t he  available  scien t i f ic  da t a  and  t he  P I ’s
extensive  personal  experience  in  t he  pedia t ric  popula t ion  (where  i t has  been  f ound  t o  be  li f e-changing) ,
prolonged  wi t hholding  o f Onabo t ulinum t oxinA  f or  t he  purpose  o f s t udy  was  no t considered  reasonable
by [CONTACT_941]  P I. Thus , a  s t udy  design  minimizing  t he  placebo  con t rol  period  while  s t ill  allowing  f or
comparison  o f Onabo t ulinum t oxinA  t o  a  con t rol  group  was  desirable . An  AB | BA  cross-over  design
(which  uses  each  pa t ien t has  his / her  own  con t rol , bo t h  minimizing  recrui t men t numbers  and  t he  need  f or
a con t rol  group  which  never  receives  t rea t men t wi t h  Onabo t ulinum t oxinA) , was  selec t ed  as  t he  bes t
option . A  f our  week  baseline  prior  t o  t rea t men t will  ac t as  a  no- t rea t men t con t rol  t o  compare  t o  bo t h  t he
treatmen t and  placebo .
The primary  ou t come  will  be  t he  di ff erence  be t ween  t rea t men t and  placebo  injec t ions  on  headache
frequency . The  di ff erence  will  be  calcula t ed  as
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 1 of 29
Where  λ  represen t s  possible  carry-over  e ff ec t s  f rom  t he  previous  t rea t men t period . Because  t he
cross-over  period  is  uni f orm  and  balanced , we  will  assume  t ha t period  e ff ec t s  and  sequence  e ff ec t s
are aliased  ou t. The  t rea t men t and  placebo  e ff ec t s  will  be  calcula t ed  as :
Where represen t s  t he  group  mean  o f t he  respec t ive  cross  over  group  periods . Given  t he  adul t
baseline  o f 19 . 9  ± 3 . 6  headache  days  per  mon t h , t he  t rea t men t reducing  t his  t o  6 . 6  days  and  t he
placebo  t o  8 . 4  days  and  assuming  a  concomi t an t reduc t ion  in  SD  since  t hese  numbers  were  no t
repor t ed  in  t he  source  manuscrip t, we  f ind  t ha t t he  e ff ec t size  f or  t his  di ff erence  (8 . 4  vs  6 . 6  wi t h  SD  1 . 35
for bo t h  groups)  is  0 . 554 , a  Cohen’s  d  o f 1 . 33 . A  power  analysis  using  a  signi f icance  level  o f 0 . 05  and  a
power  o f 0 . 9  shows  t ha t 13  subjec t s  per  group  will  be  needed  f or  t his  s t udy , or  a  t o t al  o f 26  subjec t s  (13
per group)  i f comparison  were  t o  be  made  by  [CONTACT_150781] t groupwise  t es t ing .
3. Describe  t he  secondary  s t a t is t ical  me t hod(s)  t ha t will  be  used  t o  analyze  t he  secondary
outcome(s)  or  endpoin t s .
N/A
4. If appropria t e  describe  secondary  or  pos t hoc  analyses  o f primary  ou t come(s)  or  o t her  explora t ory
analysis .
N/A
5. Sample  Size  De t ermina t ion:  Explain  how  t he  overall  t arge t sample  size  was  de t ermined  (e . g .,
power  analysis ; precision  es t ima t ion) , providing  jus t i f ica t ion  o f t he  e ff ec t size  f or  t he  primary
outcome  based  on  preliminary  da t a , curren t knowledge / li t era t ure  and / or  cos t considera t ion ; i f
appropria t e , provide  sample  size  jus t i f ica t ion  f or  secondary  ou t comes . Power  analysis  should  (a t
least )  ma t ch  t he  primary  ou t come / endpoin t.
Given  t he  adul t baseline  o f 19 . 9  ± 3 . 6  headache  days  per  mon t h , t he  t rea t men t reducing  t his  t o  6 . 6  days
and t he  placebo  t o  8 . 4  days  and  assuming  a  concomi t an t reduc t ion  in  SD  since  t hese  numbers  were  no t
repor t ed  in  t he  manuscrip t, we  f ind  t ha t t he  e ff ec t size  f or  t his  di ff erence  (8 . 4  vs  6 . 6  wi t h  SD  1 . 35  f or
both groups)  is  0 . 554 , a  Cohen’s  d  o f [ADDRESS_871674] I ON  7:  R I SK  ASSESSMENT  AND  POSS I BLE  BENEF I TS
A. R i sk  Assessment
1. Indica t e  t he  appropria t e  level  o f review  o f t his  s t udy , based  upon  your  risk  assessmen t.
[ X ] This  s t udy  involves  grea t er  t han  minimal  risk  t o  subjec t s  and  requires  Full  Commi tt ee  review . Skip
to Sec t ion  7 . B .
[ ] This  s t udy  involves  no  more  t han  minimal  risk  and  quali f ies  as  Exped i ted  research .
2. If t his  s t udy  involves  no  more  t han  minimal  risk , provide  jus t i f ica t ion  f or  t he  level  o f review  and  f or
all applicable  Expedi t ed  Ca t egories  you  have  chosen .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 2 of 29
B. R i sks  and  D i scomforts
1. Describe  and  assess  any  reasonably  f oreseeable  risks  and  discom f or t s  —  physical , psychological ,
social , legal  or  o t her . I nclude  an  assessmen t o f t heir  expec t ed  f requency  (e . g ., common  –  65% , less
common  –  40% , unlikely  –  5% , rare  -  <1%)  and  t he  seriousness  (mild , modera t e , severe) . A  bulle t
point lis t is  recommended . If t his  s t udy  will  involve  t he  collec t ion  o f iden t i f iable  priva t e  in f orma t ion ,
even  t emporarily , f or  which  t he  disclosure  o f t he  da t a  ou t side  o f t he  research  could  reasonably  place
the subjec t s  a t risk , include  t he  risk  o f a  po t en t ial  breach  o f con f iden t iali t y .
As lis t ed  in  t he  Risks  sec t ion  o f t he  I n f ormed  Consen t.
2. Discuss  wha t s t eps  have  been  t aken  and / or  will  be  t aken  t o  preven t and  minimize  any  risks / po t en t ial
discom f or t s  t o  subjec t s . Examples  include : designing  t he  s t udy  t o  make  use  o f procedures  involving
less risk  when  appropria t e ; minimizing  s t udy  procedures  by  t aking  advan t age  o f clinical  procedures
conduc t ed  on  t he  subjec t s ; mi t iga t ing  risks  by  [CONTACT_649963] t oring  or  conduc t ing  suppor t ive
inven t ions  f or  t he  s t udy ; implemen t securi t y  provisions  t o  pro t ec t con f iden t ial  in f orma t ion .
All ex t rac t ed  da t a  will  be  de-iden t i f ied  immedia t ely  and  save  on  a  secured  da t abase  f or  research
purposes  only . S t udy  t eam  members  will  f ollow  s t ric t ly  t he  repor t ing  guideline  by  I RB  in  case  o f a  breach
of con f iden t iali t y , which  is  nearly  impossible  since  all  da t a  are  de-iden t i f ied . Regardless , all  collec t ed
informa t ion  will  be  securely  s t ored  on  a  password -pro t ec t ed  server .
Subjec t s  f or  t his  s t udy  will  be  closely  moni t ored  f or  any  po t en t ial  adverse  even t s . Subjec t s  will  be  able
to call  t he  Lead  Researcher  24  hours  a  day  f or  any  po t en t ial  issues .
C. Potent i a l Benef i ts
1. Describe  t he  po t en t ial  bene f i t s  subjec t s  may  expec t t o  receive  f rom  par t icipa t ion  in  t his  s t udy .
Compensa t ion  is  no t a  bene f i t; do  no t include  i t in  t his  sec t ion .
[ ] There  is  no  direc t bene f i t an t icipa t ed  f or  t he  subjec t s .
There  is  a  prospec t o f direc t bene f i t t o  children  par t icipa t ing  in  t he  s t udy . Taking  par t in  t his  s t udy  may
or may  no t make  your  heal t h  be tt er  wi t h  t he  f irs t t wo  t rea t men t s . While  researchers  hope  Bo t ox®  will
be more  e ff ec t ive  t han  t he  s t andard  (usual)  t rea t men t, t here  is  limi t ed  proo f o f t his  ye t.
2. Speci f y  t he  expec t ed  po t en t ial  socie t al / scien t i f ic  bene f i t (s)  o f t his  s t udy .
Overriding  Ra t ionale
Onabo t ulinum t oxinA  (Bo t ox  ®)  injec t ions  have  been  shown  t o  provide  chronic  pain  relie f in  pa t ien t s
aged  >18  wi t h  migraine  pain . However , t here  is  limi t ed  li t era t ure  on  pain  relie f in  pedia t ric  pa t ien t s
receiving  Bo t ox  ®  injec t ions  f or  chronic  migraine  pain  [ 15 , 16 ]. A  PubMed  search  displays  very  f ew
resul t s  on  publica t ions  involving  t he  s t udy  o f t he  e ff ec t iveness  o f Bo t ox  ®  injec t ions  in  pedia t ric
patien t s . The  s t udies  t ha t are  published  involve  Bo t ox  ®  injec t ions  done  f or  t he  t rea t men t o f migraines
and chronic  headaches  in  adul t s  [ 17 , 19 , 23 , 24 ] or  are  largely  re t rospec t ive  reviews . Moreover , t he
resul t s  o f t hese  s t udies  vary  and  have  no t es t ablished  whe t her  or  no t t he  procedure  is  bene f icial  by
[CONTACT_649964] t ive  randomized  t rials . Chronic  headache  pain  is  one  o f t he  mos t common  presen t ing  complain t
to a mul t i-disciplinary  pain  cen t er  specializing  in  pedia t ric  pain , and  t he  mos t common
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 3 of 29
presen t ing  complain t t o  a  pedia t ric  neurology  prac t ice . It resul t s  in  a  global  heal t h  concern  bo t h  in
terms  o f economic  and  f unc t ional  disabili t y  t o  pa t ien t and  f amily , bu t also  in  skyrocke t ing  heal t h  care
utiliza t ion  and  pharmacy  cos t s  t o  t he  US  heal t hcare  sys t em . If migraines  can  be  prophylaxed  by  t he
BOTOX  ®  modali t y  in  children , t hese  ups t ream  and  downs t ream  cos t s  and  disabili t y  can  be  cur t ailed .
With t he  encouraging  da t a  in  adul t s  wi t h  chronic  migraine  presen t ed  a t t he  14 th Congress  o f t he
Interna t ional  Headache  Socie t y  (Philadelphia , PA  2009)  and  t he  PREEMPT  t rials , and  wi t h  t he
experiences  o f t he  above  ci t ed  re t rospec t ive  case  series , i t cer t ainly  appears  reasonable  t o  f ur t her
explore  a  po t en t ial  role  f or  Onabo t ulinum t oxinA  in  t he  managemen t o f chronic  migraine  in  t he  pedia t ric
popula t ion  [ 14 , 15 ]. The  overr i d i ng  rat i ona l e  i s  to  demonstrate  eff i cacy , to l erab ili ty  and  safety  of
Onabotu li numtox i nA  for  ped i atr i c  m i gra i ne  and  thereby  [CONTACT_649965] i a ll y  hasten  the  l engthy  process
to eva l uate  Botox®  for  approva l i n  the  ped i atr i c  popu l at i on . The  mos t urgen t goals  as  concerns
pharmaceu t ical  innova t ion  is  t he  developmen t o f pa t homechanism-based  an t imigraine  drugs  and
personalized  t herapy  t ailored  t o  t he  children  and  adolescen t s  su ff ering  wi t h  migraine . [ 13 ]
SECT I ON  8 :  ALTERNAT I VES  TO  PART I C I PAT I ON
Describe  t he  al t erna t ives  t o  par t icipa t ion  in  t he  s t udy  available  t o  prospec t ive  subjec t s . I nclude  rou t ine
(standard  o f care)  op t ions  as  well  as  o t her  experimen t al  op t ions , as  applicable .
[ ] No  al t erna t ives  exis t. The  only  al t erna t ive  t o  s t udy  par t icipa t ion  is  no t t o  par t icipa t e  in  t he  s t udy .
[ X ] There  are  rou t ine  s t andard  o f care  al t erna t ives  available ; speci f y :
Ge tt ing  no  t rea t men t
Ge tt ing  s t andard  t rea t men t f or  your  condi t ion  wi t hou t being  in  a  s t udy .
Ge tt ing  a  di ff eren t experimen t al  t rea t men t/t aking  par t in  ano t her  s t udy .
[ ] There  are  o t her  al t erna t ives  t o  s t udy  par t icipa t ion ; speci f y : <Type  here>
SECT I ON  9:  SUBJECT  COSTS
1. Indica t e  below  i f subjec t s  or  t heir  insurers  will  be  charged  f or  s t udy  procedures . I den t i f y  and
describe  t hose  cos t s .
[ ] No t applicable : This  s t udy  involves  no  in t erac t ion / in t erven t ion  wi t h  research  subjec t s . Skip  t o
Section  10 .
[ X ] This  s t udy  involves  in t erac t ion / in t erven t ion  wi t h  research  subjec t s ; however  t here  are  no  cos t s  t o
subjec t s / insurers .
[ ] This  s t udy  involves  in t erac t ion / in t erven t ion  wi t h  research  subjec t s , and  t here  are  cos t s  t o
subjec t s / insurers :
2. If subjec t s  or  t heir  insurers  will  be  responsible  f or  s t udy-rela t ed  cos t s , explain  why  i t is  appropria t e
to charge  t hose  cos t s  t o  t he  subjec t s  or  t heir  insurers . Provide  suppor t ing  documen t a t ion  as
applicable  (e . g ., s t udy  procedures  include  rou t ine  (s t andard  o f care)  procedures ; FDA
IDE/HDE /I ND  le tt er  t ha t suppor t s  billing  t o  subjec t s) .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 4 of 29
[ X ] No t applicable : The  s t udy  involves  no  cos t s  t o  subjec t s  f or  s t udy  par t icipa t ion .
[ ] S t udy  rela t ed  cos t s  will  be  billed  t o  subjec t s  or  t heir  insurers  f or  t he  f ollowing  reasons :
SECT I ON  10:  SUBJECT  COMPENSAT I ON  AND  RE I MBURSEMENT
1. If subjec t s  will  be  compensa t ed  f or  t heir  par t icipa t ion , explain  t he  me t hod /t erms  o f paymen t (e . g .,
money ; check ; ex t ra  credi t; gi ft cer t i f ica t e) .
[] No t applicable : This  s t udy  involves  no  in t erac t ion / in t erven t ion  wi t h  research  subjec t s . Skip  t o
Section  11 .
[ X ] No  compensa t ion  will  be  provided  t o  subjec t s .
[ ] Compensa t ion  will  be  provided  t o  subjec t s  in  t he  f orm  o f cash / gi ft cer t i f ica t e .
[ ] Compensa t ion  will  be  provided  t o  subjec t s  in  t he  f orm  o f a  check  issued  t o  t he  subjec t s  t hrough
the UC I Accoun t ing  O ff ice . The  subjec t ’s  name , address , and  social  securi t y  number , will  be
released  t o  t he  UC I Accoun t ing  O ff ice  f or  t he  purpose  o f paymen t and  f or  t ax  repor t ing  t o  t he
Internal  Revenue  Service  ( I RS) .
[ ] O t her
2. Speci f y  t he  schedule  and  amoun t s  o f compensa t ion  (e . g ., a t end  o f s t udy ; a ft er  each  session / visi t )
including  t he  t o t al  amoun t subjec t s  can  receive  f or  comple t ing  t he  s t udy . Compensa t ion  should  be
offered  on  a  prora t ed  basis  when  t he  research  involves  mul t iple  visi t s .
For compensa t ion  ≥ $600 , subjec t names  and  social  securi t y  numbers  mus t be  collec t ed . This
informa t ion  mus t be  repor t ed  t o  UC I Accoun t ing  f or  t ax-repor t ing  purposes .
[ X ] No t applicable : This  s t udy  involves  no  compensa t ion  t o  subjec t s .
Subjec t s  will  be  compensa t ed  wi t h  t he  f ollowing  schedule  and  amoun t s :
3. Speci f y  whe t her  subjec t s  will  be  reimbursed  f or  ou t -o f pocke t expenses . If so , describe  any
requiremen t s  f or  reimbursemen t (e . g ., receip t ) .
[ X ] No t applicable : This  s t udy  involves  no  reimbursemen t t o  subjec t s .
Subjec t s  will  be  reimbursed ; speci f y :
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  [ADDRESS_871675] I ON  11:  CONF I DENT I AL I TY  OF  RESEARCH  B I OSPEC I MENS / DATA
A. B i ospec i mens / Data  Storage
1. Indica t e  all  subjec t iden t i f iers  t ha t may  be  included  wi t h  t he  biospecimens  or  collec t ed  f or  t he
research  s t udy . If any  s t udy-rela t ed  da t a  will  be  derived  f rom  a  medical  record , added  t o  a  medical
record , crea t ed  or  collec t ed  as  par t o f heal t h  care , or  used  t o  make  heal t h  care  decisions  t he  H I PAA
policy  applies . The  subjec t ’s  H I PAA  Research  Au t horiza t ion  is  required  or  a  waiver  o f H I PAA
Research  Au t horiza t ion  mus t be  reques t ed  by  [CONTACT_427544] t ing  Appendix  T .
[ ] This  s t udy  does  no t involve  t he  collec t ion  o f subjec t iden t i f iers .
Check  all  t he  f ollowing  subjec t iden t i f iers  will  be  used , crea t ed , collec t ed , disclosed  as  par t o f t he
research :
[ X ] Names [  ]  Social  Securi t y  Numbers [  ]  Device  iden t i f iers / Serial  numbers
[ X ]  Da t es* [  X  ]  Medical  record  numbers [  ]  Web  URLs
[ ] Pos t al  address [  ]  Heal t h  plan  numbers [  ]  I P  address  numbers
[ X ] Phone  numbers [  ]  Accoun t numbers [  ]  Biome t ric  iden t i f iers
[ ] Fax  numbers
[ ] Email  address[ ] License / Cer t i f ica t e  numbers
[ ] Vehicle  id  numbers[ ] Facial  Pho t os /I mages
[ ] Any  o t her  unique  iden t i f ier
[ ] O t her  (Speci f y  all) : <Type  here>
* birth  da t e , t rea t men t/ hospi t aliza t ion  da t es
Indica t e  how  da t a  will  be  s t ored  and  secured , including  elec t ronic  da t a  as  well  as  hardcopy  da t a  paper
records , elec t ronic  f iles , audio / video  t apes , biospecimens , e t c . If t he  research  da t a  includes  subjec t
ident i f iable  da t a  and / or  Pro t ec t ed  Heal t h  I n f orma t ion , t he  s t orage  devices  or  t he  elec t ronic  research
files mus t be  encryp t ed . [ For  guidance  on  t he  use  o f cloud  services , please  review  t he  UC I O I T  policy . ]
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 6 of 29
Electron i c  Data / F il es  (check  a ll that  app l y):
[ ] Anonymous  da t a  will  be  main t ained ; no  subjec t iden t i f iers
[ X ]  Coded  da t a ; code  key  is  kep t separa t e  f rom  da t a  in  secure  loca t ion .
[ ] Da t a  includes  subjec t iden t i f iable  in f orma t ion . Provide  ra t ionale  f or  main t aining  subjec t iden t i f iable
info):  <Type  here>
[ X ]  Da t a  will  be  s t ored  on  secure  ne t work  server .
[ ] Da t a  will  be  s t ored  on  s t andalone  desk t op  compu t er  (no t connec t ed  t o  ne t work / in t erne t )
[ ] O t her  (speci f y  here) : <Type  here>
Hardcopy  Data  (Records , Record i ngs , Photographs)  and  B i ospec i mens  (check  a ll that  app l y):
[ ] Anonymous  biospecimens / da t a  will  be  main t ained ; no  subjec t iden t i f iers
[ X ]  Coded  da t a ; code  key  is  kep t separa t e  f rom  biospecimens / da t a  in  secure  loca t ion .
[ ] Biospecimens / Da t a  includes  subjec t iden t i f iable  in f orma t ion  (Provide  ra t ionale  f or  main t aining
subjec t iden t i f iable  in f o):  <Type  here>
[ X ]  Da t a  will  be  s t ored  in  locked  f ile  cabine t or  locked  room .
[ ] Biospecimens  will  be  s t ored  in  locked  lab / re f rigera t or /f reezer .
[ ] O t her  (speci f y  here) : <Type  here>
2. Lis t t he  loca t ion(s)  where  t he  da t a  and / or  biological  specimens  will  be  s t ored .
The da t a  will  be  s t ored  in  a  secure , locked  f acili t y  in  t he  UC I Anes t hesia  Research  Depar t men t f or  t he
durat ion  o f t he  s t udy  approval . Only , t he  inves t iga t ors  and  s t udy  personnel  will  have  access  t o  t he
data. Any  da t a  collec t ed  on  t he  compu t er  will  only  be  s t ored  on  a  secure , encryp t ed  server . Da t a  will
be re t ained  f or  six  years  as  t his  research  involves  Pro t ec t ed  Heal t h  I n f orma t ion .
3. If subjec t iden t i f iable  da t a  will  be  t ranspor t ed  or  main t ained  on  por t able  devices , explain  why  i t is
necessary  use  t hese  devices . Only  t he  “minimum  da t a  necessary ”  should  be  s t ored  on  por t able
devices  as  t hese  devices  are  par t icularly  suscep t ible  t o  loss  or  t he ft. If t here  is  a  necessi t y  t o  use  a
portable  device  f or  t he  ini t ial  collec t ion  o f iden t i f iable  priva t e  in f orma t ion , t he  research  f iles  mus t be
encryp t ed , and  subjec t iden t i f iers  t rans f erred  t o  a  secure  sys t em  as  soon  as  possible .
[ X ] No t applicable : Research  da t a  will  no t be  t ranspor t ed  or  main t ained  on  por t able  devices .
Research  da t a  will  need  t o  be  main t ained  on  t he  f ollowing  por t able  device(s)  f or  t he  f ollowing
reason(s) : <Type  here>
B. Data  and / or  B i o l og i ca l Spec i mens  Access
Speci f y  who  will  have  access  t o  subjec t iden t i f iable  da t a  and / or  biological  specimens  as  par t o f t his
study .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 7 of 29
[ ] No t applicable : No  subjec t iden t i f iers  will  be  collec t ed .
[ X ]  Au t horized  UC I personnel  such  as  t he  research  t eam  and  appropria t e  ins t i t u t ional  o ff icials , t he
study  sponsor  or  t he  sponsor’s  agen t s  (i f applicable) , and  regula t ory  en t i t ies  such  as  t he  Food  and
Drug  Adminis t ra t ion  (FDA) , t he  O ff ice  o f Human  Research  Pro t ec t ions  (OHRP) , and  t he  Na t ional
Instit u t es  o f Heal t h  (N I H) .
[ ] O t her : <Type  here>
C. Data  and / or  B i o l og i ca l Spec i mens  Retent i on
Indica t e  how  long  subjec t iden t i f iable  da t a  and / or  biological  specimens , including  t he  subjec t code  key
will be  re t ained . If more  t han  one  o f t he  op t ions  below  is  applicable  (e . g ., t he  s t udy  involves  children) ,
records  mus t be  kep t f or  t he  longer  period .
[ ] No t applicable : No  subjec t iden t i f iable  research  da t a  will  be  re t ained .
[ X ]  Separa t e  code  key  will  be  des t royed  or  subjec t iden t i f iable  in f orma t ion  will  be  removed  f rom  t he
biospecimens  and / or  da t a  a t t he  earlies t convenience , consis t en t wi t h  t he  conduc t o f t his  research .
Speci f y  t ime f rame : <Type  here>
[ ] Des t royed  once  research  da t a  is  analyzed .
[ ] Des t royed  a ft er  publica t ion / presen t a t ion .
[ ] Will  be  main t ained ; speci f y  t ime  f rame  and  provide  t he  ra t ionale : <Type  here>
[ ] Will  be  s t ored  and  main t ained  in  a  reposi t ory  f or  f u t ure  research  purposes .
Comple t e  Appendix  M
[ X ]  Will  be  re t ained  f or  six  years  as  t his  research  involves  Pro t ec t ed  Heal t h  I n f orma t ion  (PH I )  (e . g ., I RB
documen t a t ion , consen t/ assen t f orms  –  NOT  t he  ac t ual  PH I ) . I nves t iga t ors  mus t des t roy  PH I a t t he
earlies t oppor t uni t y , consis t en t wi t h  t he  conduc t o f t his  s t udy , unless  t here  is  an  appropria t e
justifica t ion  f or  re t aining  t he  iden t i f iers  or  as  required  by  [CONTACT_2371] .
[ X ] Will  be  re t ained  f or  seven  years  a ft er  all  children  enrolled  in  t he  s t udy  reach  t he  age  o f majori t y
[age 18  in  Cali f ornia ] as  t his  s t udy  includes  children .
[ ] Will  be  re t ained  25  years  a ft er  s t udy  closure  as  t his  s t udy  involves  in  vi t ro  f er t iliza t ion  s t udies  or
research  involving  pregnan t women .
[ ] Will  be  re t ained  f or  t wo  years  a ft er  an  approved  marke t ing  applica t ion , as  t his  is  a  FDA  regula t ed
study . If approval  is  no t received , t he  research  records  will  be  kep t f or  2  years  a ft er  t he  inves t iga t ion
is discon t inued  and  t he  FDA  is  no t i f ied .
[ ] O t her : <Type  here>
D. Photographs , Aud i o / V i deo  Record i ngs  Retent i on
1. If subjec t iden t i f iable  audio  or  video  recordings  will  be  collec t ed , speci f y  t he  t ime f rame  f or  t he
transcrip t ion  and  describe  re t en t ion / des t ruc t ion  plans .
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 8 of 29
[ X ]  No t applicable : Subjec t iden t i f iable  audio / video  recordings  will  no t be  collec t ed .
[ ] Audio  or  video  recordings  t ranscribed ; speci f y  t ime  f rame : <Type  here>
[ ] Audio  or  video  recordings  will  be  main t ained ; speci f y  t ime  f rame : <Type  here>
[ ] Audio  or  video  recordings  main t ained  inde f ini t ely ; provide  t he  ra t ionale : <Type  here>
[ ] Audio  or  video  recordings  des t royed ; speci f y  t ime  f rame : <Type  here>
2. If subjec t iden t i f iable  pho t ographs  will  be  collec t ed , describe  re t en t ion / des t ruc t ion  plans .
[ X ]  No t applicable : Subjec t iden t i f iable  pho t ographs  will  no t be  collec t ed .
[ ] Pho t ographs  will  be  main t ained ; speci f y  t ime  f rame : <Type  here>
[ ] Pho t ographs  main t ained  inde f ini t ely ; provide  t he  ra t ionale : <Type  here>
[ ] Pho t ographs  des t royed ; speci f y  t ime  f rame : <Type  here>
E. Cert i f i cate  of  Conf i dent i a li ty
1. Indica t e  whe t her  a  Cer t i f ica t e  o f Con f iden t iali t y  (COC)  has  been  or  will  be  reques t ed .
[ X ] No t applicable : No  COC  has  been  reques t ed  f or  t his  s t udy .
[ ] A  COC  will  be  or  has  been  reques t ed  f or  t his  s t udy . The  COC  applica t ion  mus t be  submi tt ed  t o  t he
IRB s t a ff f or  review  a ft er  I RB  approval .
[ ] A  COC  has  been  ob t ained  f or  t his  s t udy . The  expi[INVESTIGATOR_20116] t ion  da t e  o f t his  COC  is : <Type  here>
Provide  a  copy  o f t he  COC  Approval  Le tt er .
2. Explain  in  wha t si t ua t ions  t he  UC I s t udy  t eam  will  disclose  iden t i f iable  priva t e  in f orma t ion  pro t ec t ed
by a COC .
<Type  here>
UCI IRB A pp r o v ed : 01-20-2021  | CPA #  [ZIP_CODE]  | H S #  2016 - 3108 2 9 of 29